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1. INTRODUCTION  
Phenylketonuria (PKU, OMIM #261600) is an autosomal recessive disorder of 
amino acid metabolism, wherein the level of phenylalanine (Phe) in body fluids 
is elevated due to the lack of the activity of the enzyme phenylalanine hydro-
xylase (PAH). This enzyme is normally responsible for converting dietary Phe 
into tyrosine (Tyr) of the resulting hyperphenylalaninaemia (HPA) can cause 
the build-up of cytotoxic compounds and block the transport of other amino 
acids across the blood brain barrier (BBB). These cause defects of brain 
development and severe intellectual disability if the condition is untreated. The 
treatment is primarily a special phenylalanine-free diet [Blau and Scriver 2004; 
Blau et al., 2010; Blau N 2014; Scriver 1995]. In the majority of Caucasoid 
populations PKU is one of the most frequent inherited metabolic diseases 
(IMDs) with the prevalence of approximately 1 in 10,000 [Williams et al., 
2008]. 
The basis of PKU was discovered in 1934 by a Norwegian medical doctor 
Ivar Asbjørn Følling, who detected phenylpyruvic acid in the urine of some 
severely mentally retarded patients [Centerwall and Centerwall 2000; Folling 
1994]. Furthermore, low-Phe diets were shown to improve the condition of the 
patients [Bickel et al., 1953]. These observations became the cornerstone for the 
treatment of PKU patients, who are now recommended to receive a protein-
restricted diet supplemented with amino acids, except Phe.  
PKU became the first IMD to be screened in newborns by analysing dried 
blood samples collected on filter paper, later known as Guthrie cards, named for 
the American microbiologist Robert Guthrie, who developed a bacterial inhi-
bition assay for assessing elevated Phe in blood spots [Guthrie and Susi 1963]. 
The newborn screening programmes started in the beginning of the 1960s in the 
United States and later spread into most of the Western-European countries 
[Therrell et al., 2015]. Currently, newborn screening has been expanded to 
cover various treatable IMDs, taking into account technical developments and 
the specific genetic structure of particular populations [Bodamer et al., 2007; 
Burgard et al., 2012; Landau et al., 2014; Lindner et al., 2010].  
Until the early 1990s, PKU in Estonia had been diagnosed only by the 
urinary Følling test [Folling 1994] and it had been assumed that the incidence of 
the disease was low, similar to that of the Finnish population, wherein its 
incidence had been established as about 1 in 200,000 births [Guldberg et al., 
1995]. With the shift in paradigm taking place in the beginning of the 1990s, the 
concept of newborn screening for treatable metabolic disorders was re-eva-
luated, and in 1993, the national newborn screening programme was initiated 
[Ounap et al., 1998]. Retrospectively, data about available PKU patients were 
gathered in the Department of Clinical Genetics, United Laboratories of Tartu 
University Hospital, and is now permanently upgraded under the management 
of paediatricians and clinical geneticists in the same department. Since 2014, 
newborn screening in Estonia has been upgraded to a new level, as the 
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screening procedure using tandem mass spectrometry (MS/MS) was introduced 
to enable the detection of aberrations in metabolites to diagnose 19 treatable 
IMDs [Reinson et al., 2018].  
The current study was initiated in the first half of the 1990s, when epi-
demiological study and mutation screening on Estonian PKU patients was 
performed in cooperation with Prof. K. Õunap. This is reflected in Publication I 
of the current thesis. Now, we saw an urgent need to update and refresh the 
information about PKU and to make it available to scientific and healthcare 
community. This emphasized the importance of analysing the efficiency of the 
dietary treatment and adherence of the patients and their families to the re-
commended dietary treatment, and also the need of finding the exact molecular 
lesion in the only Estonian patient with dihydropteridine reductase (DHPR) 
deficiency. 
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2. LITERATURE REVIEW  
2.1. Phenlyalanine metabolism 
Phenylalanine (Phe) is an essential amino acid regularly present in excess in 
nutritional proteins. In a normally functioning organism, the excess Phe is con-
verted to tyrosine (Tyr) by phenylalanine hydroxylase (L-phenylalanine-4-
monooxygenase, PAH, EC 1.14.16.1), which is the enzyme carrying out the 
obligatory and rate-limiting step in the catabolic pathway that leads finally to 
complete oxidation of Phe to CO2 and water. The minimum requirements for a 
normal phenylalanine hydroxylation reaction by this enzyme are the presence of 
the cytosolic liver enzyme PAH, oxygen, L-phenylalanine, and the tetrahydro-
biopterin (BH4) cofactor [Scriver et al., 1994]. Alternatively, if the function of 
PAH is disturbed, transamination of excess Phe to phenylpyruvate following 
subsequent metabolism takes place, producing elevated levels of the neurotoxic 
compounds phenyllactate, phenylacetate, o-hydroxyphenylacetate and phenyl-
acetylglutamate as well as decarboxylation to phenylethylamine (Figure 1) 
[Rausell et al., 2019; Williams et al., 2008].  
Human PAH is a tetrameric enzyme composed of identical subunits [Fu- 
setti et al., 1998], which are encoded by a single gene PAH (phenylalanine  
hydroxylase, OMIM *612349). The activity of this enzyme is regulated by 
phosphorylation/dephosphorylation. PAH activity is increased several times if 
phosphorylated by a cAMP-dependent protein kinase in rat, particularly by 
phosphorylation of serine at position 16 [Citron et al., 1994]. Human PAH is 
substantially maintained in an activated form and in vitro studies have demon-
strated only moderate additional activation by phosphorylation [Kowlessur et 
al., 1996]. Each monomer (Figure 2) consists of three functional domains: an N-
terminal regulatory domain (residues 1–142); a catalytic domain (residues 143–
410) that includes binding sites for Fe3+ ion, which is reduced to the active Fe2 + 
form upon binding of the cofactor; and a C-terminal oligomerisation domain 
(residues 411–452) with dimerisation (residues 411–426) and tetramerisation 
motifs (residues 427–452) [Flatmark and Stevens 1999; Fusetti et al., 1998; 
Kobe et al., 1999]. The internal regions of the protein are very highly homo-
logous to those of the other aromatic amino acid (tyrosine and tryptophan) 
hydroxylases (TYH, TPH). These common sequences are conserved around five 
cysteine residues [Grenett et al., 1987]. The full activation of PAH occurs only 
in the presence of the natural cofactor BH4 and a non-heme iron atom. PAH is 
expressed mainly in the liver [Ayling et al., 1974], and additionally in the 
kidney [Lichter-Konecki et al., 1999; Rao and Kaufman 1986]. 
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Figure 1. Under normal circumstances, phenylalanine (Phe) coming from the dietary 
contribution and endogenous protein is metabolized to tyrosine (Tyr) by phenylalanine 
hydroxylase (PAH) with the concourse of tetrahydrobiopterin, oxygen, and iron. In 
addition, Phe is converted by the action of Phe-decarboxylase to phenylethyamine. 
Patients with phenylketonuria (PKU) lack PAH, and as a consequence Phe plasma 
levels increase to toxic levels in the brain. Excess Phe is converted into phenylpyruvate, 
phenylacetate, and phenyllactate that are highly toxic for the brain. Phe competes with 
the other large neutral aminoacids (LNAA) for the same large amino acid transporter 1 
(LAT-1) to cross the blood–brain barrier (BBB). In addition, circulating Tyr decreases 
and subsequently the synthesis of metabolites such as dopamine, noradrenaline, and 
adrenaline diminishes. The consequence of these metabolic alterations is a protracted 
brain damage [Rausell et al., 2019]. 
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Figure 2. The 3D crystal structure of the PAH monomer. In the active site, the iron 
atom and BH4 cofactor are shown in red. BH4-responsive variations found in PKU 
patients are mapped in the structure. The N-terminus starting over the active site as well 
as the rest of the regulatory domain are highlighted in red; catalytic domain in blue; and 
tetramer domain is in purple. In the top right corner is the native tetramer form of the 
enzyme. From [Zurfluh et al., 2008]. 
 
 
PAH together with tyrosine hydroxylase (EC 1.14.16.2) and two isoforms of 
tryptophan hydroxylases (EC 1.14.16.4) make up the family of pterin-dependent 
aromatic amino acid hydroxylases (AAAHs) (Figure 3). The genes encoding 
these enzymes apparently evolved by duplication and divergence, beginning 
about 750 million years ago [Grenett et al., 1987; Xu et al., 2019]. The enzymes 
are 60% identical over their 330 C-terminal amino acids. All three enzymes are 
being phosphorylated at amino acid residues in the N-termini, although the 
effects of phosphorylation differ. The N-terminus of PAH contains an allosteric 
activation site dependent on the substrate – phenylalanine. Recombinant PAH 
with the deletion of 116 N-terminal amino acids remains active, but is not 
regulated by the substrate [Daubner et al., 1997]. 
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Figure 3. The metabolic pathways connected to the hydroxylation of aromatic amino 
acids are indicated. GTP-CH (GTP-cyclohydrolase), PTS (6-pyruvyltetrahydrobiopterin 
synthase), AR (aldose reductase) and/or SR (sepiapterin reductase) are all involved in 
the biosynthesis of BH4 from GTP. Pterin 4α-carbinolamine dehydratase (PCD) and 
dihydropteridine reductase (DHPR) are involved in the regeneration of BH4 and act 
upon the substrates 4α-hydroxy-BH4 (or 4α-carbinolamine) and q-BH2 (quinonoid 
dihydrobiopterin) respectively. PAH, TYH and TPH catalyse the hydroxylation of 
phenylalanine, tyrosine and tryptophan to tyrosine, 3,4-dihydroxyphenylalanine (L-
Dopa) and 5'-hydroxytryptophan  (5-HT, 5-hydroxytryptamine, serotonin), respectively. 
Additionally, BH4 catalyses NO synthesis from arginine to NO and citrulline by NOS 
(nitric oxide synthase). Adapted from [Hufton et al., 1995]. 
   
 
2.2. Biopterin metabolism 
The BH4 cofactor plays two independent roles in PAH: it acts both as a cofactor 
and as a negative regulator, at least in case of the tetrameric form of the enzyme 
[Davis et al., 1996]. Nomenclaturally, BH4 is called 2-amino-4-hydroxy-6-(L-
erythro-1,2-dihydroxypropyl)-tetrahydropteridine. It is synthesised in mammals 
via a pathway starting from the nucleotide guanosine triphosphate (GTP). GTP 
is converted to D-erythro-7,8-dihydroneopterin triphosphate by GTP-cyclo-
hydrolase (GTPCH; EC 3.5.4.16). The subsequent pathway involves the re-
action catalysed by 6-pyruvoyltetrahydropterin synthase (PTS; EC 4.6.1.10), 
historically called the “phosphate eliminating enzyme”. The product of PTS, 6-
pyruvoyltetrahydropterin (6-PTP), is converted to BH4 in the presence of 
NADPH and sepiapterin reductase (SR, EC 1.1.1.153) [Kim and Park 2010; 
Thony et al., 2000].  
Similarly to the phenylalanine hydroxylation reaction, BH4 is oxidised in the 
course of the hydroxylation reaction of the aromatic amino acids tyrosine and 
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tryptophan, catalysed by TYH and TPH, respectively (Figure 4). These amino 
acids are the essential precursors of the neurotransmitters dopamine (and sub-
sequently other catecholamines) and serotonin. Tyr is hydroxylated to 3,4-di-
hydroxyphenylalanine (L-Dopa), which is the rate limiting step in the bio-
synthesis of catecholamines [Hufton et al., 1995]. Additionally, the importance 
of BH4 for the full activity of nitric oxide synthases (NOS; EC 1.14.13.39) 
[Mayer et al., 1991] has been described as another possible origin of the patho-
genic processes in BH4 deficiencies [Werner et al., 2011]. In total, BH4 is a 
cofactor for all AAAHs and three NOS isoforms, as well as the glyceryl-ether 
mono-oxygenase [Thony et al., 2000; Watschinger et al., 2009] 
When aromatic amino acid hydroxylases perform the hydroxylation reaction, 
BH4 is converted to pterin-4α-carbinolamine. The 4α-carbinolamine then 
undergoes a pterin-4α-carbinolamine dehydratase (PCD)-catalysed dehydration 
reaction and quinonoid dihydrobiopterin (qBH2) is formed [Lei and Kaufman 
1998]. This substance has no catalytic activity in the hydroxylation reaction 
performed by AAAHs and must be reduced back to BH4 by the NADH-
dependent dihydropteridine reductase (DHPR; EC 1.6.99.7). DHPR is a unique 
enzyme with no related gene sequences known in human genome and it is 
present in an active form in all tissues. In the absence of regeneration performed 
by DHPR, the hydroxylation reaction of Phe is stoichiometric for BH4, i.e. one 
BH4 added yields one tyrosine residue formed [Werner et al., 2011]. 
 
 
 
 
Figure 4. Simplified metabolic pathway of the synthesis and regeneration of tetrahydro-
biopterin, and its implication in the synthesis of neurotransmitters [Dhondt 2010]. 
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2.3. The phenylalanine hydroxylase gene 
The human PAH locus has been mapped to chromosome 12q23.2 [Lidsky et al., 
1985]. The first results in cloning human PAH were available in 1983 [Woo et 
al., 1983]. The cDNA of human PAH was cloned in 1985 [Kwok et al., 1985], 
and was shown to contain 2448 bases, with an open reading frame of 1356 bp 
capable of encoding a 452 amino acid protein monomer with a putative mole-
cular weight of 51,672 daltons. The structure of the PAH gene was revealed in 
1986, showing the whole peptide-coding region to span over 121.5 kb of 
genomic DNA and contain 13 coding exons, with intron sizes ranging from 1 to 
23 kb [DiLella et al., 1986]. The schematic presentation of PAH is shown in 
Figure 5.  
 
 
Figure 5. Structure of the human PAH gene. A) The horizontal line represents the full 
length of the PAH gene, spanning 79.3 kb. Each vertical bar represents an exon. The 
location of the start codon ATG in exon 1 is indicated (+1). B) Schematic representation 
of PAH mRNA. The vertical lines mark the boundaries between exons. The three 
functional domains of PAH are coloured purple for the regulatory domain, light green 
for the catalytic domain and orange for the tetramerisation domain [Ho and Christo-
doulou 2014]. 
 
 
Genetic alterations in PAH that cause the elevation of Phe in the human orga-
nism differ significantly between populations and geographical gradients of 
variations can be observed. In spite of the high number of described mutations, 
five molecular lesions are most prevalent among Caucasians [Eisensmith et al., 
1992], which together usually cover more than half of the affected alleles in a 
population. Namely, these variations are p.Arg158Gln, p.Arg261Gln, c.1066-
11G>A, p.Arg408Trp and c.1315+1G>A. 
The number of reported variations in PAH is currently approaching one 
thousand (Table 1). Given the location of each particular variation in the gene 
and the character of amino acid substitutions, the phenotypes, together with the 
personal efficacy of modifications of treatment, can vary widely. These varia-
tions may involve complete lack of enzyme activity, responsiveness of the con-
centrations of the substrate (Phe) and cofactor (BH4), modifications in protein 
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folding and tetramerisation, and response to the concentration of cofactor as a 
chaperon. Several more frequent variations have been assessed by in vitro 
assays [Danecka et al., 2015], providing clues to personalised approach to 
treatment.  
 
 
2.4. Phenylketonuria (PKU), a metabolic condition 
occurring due to PAH deficiency 
Phenylketonuria (PKU, OMIM #261600) is an autosomal recessive disorder of 
amino acid metabolism, wherein the lack of the activity of PAH converting Phe 
to Tyr leads to accumulation of Phe in the blood and brain. Untreated PKU is 
characterised by irreversible intellectual disability, microcephaly, motor defi-
cits, eczematous rash, autism, seizures, developmental problems, aberrant beha-
viour and psychiatric symptoms. The precise pathogenesis of brain dysfunction 
is still unclear [van Wegberg et al., 2017]. 
Historically, accumulation of toxic metabolites has been considered one of 
the main factors in brain damage occurring in PKU; additionally lack of other 
large neutral amino acids (LNAAs) as well as oxidative stress together with dis-
turbances in energy metabolism in brain is now taken into account as important 
causes that impact in the pathogenesis of PKU [Kyprianou et al., 2009].  
A few pathogenic mechanisms have been proposed to be underlying the 
deleterious effects of elevated Phe in case of PKU. The excessive accumulation 
of Phe in plasma and tissues and its metabolites phenylpyruvate, phenyllactate, 
and phenylacetate, collectively known as phenylketones, provides a set of bio-
chemically detectable compounds characteristic to PKU. These compounds ex-
hibit toxicity to the developing brain, probably via several mechanisms, e.g. by 
inhibiting antioxidative enzymes like superoxide dismutase and glucose-6-
phosphate dehydrogenase [Moraes et al., 2013; Rosa et al., 2012] and thereby 
inducing oxidative stress. Elevated level of Phe also affects neurotransmitter 
homeostasis in the developing brain, energy production, and protein synthesis. 
Transamination of Phe to form phenylpyruvate usually starts if Phe concentra-
tion exceeds 1.2 mmol/L. LNAAs need the same active transport channel as Phe 
for crossing BBB. Thus, the elevated Phe levels are considered to act as a com-
petitive inhibitor of transport of other LNAAs across the BBB, reducing the 
entrance of Trp into cerebrospinal fluid (CSF) and thereby interfering with the 
production of serotonin [de Groot et al., 2010]. Moreover, phenylpyruvic, 
phenyllactic and phenylacetic acids are known to be inhibitors of 5-hydro-
xytryptophan decarboxylase, leading to a decrease in serotonin synthesis.  De-
creased amounts of adrenaline, noradrenaline and dopamine may be caused by 
the inhibition of dopamine decarboxylase. The toxic metabolites of Phe also 
inhibit glutamic acid decarboxylase, thereby decreasing the levels of 4-amino-
butyric acid (GABA), an important neurotransmitter, which regulates neuronal 
excitability. Additionally, disturbed protein synthesis, lipid metabolism, bio-
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energetics, and even calcium homeostasis may all contribute to the pathogenesis 
of untreated PKU [Schuck et al., 2015]. 
The mechanisms brought out above occur in persons with PKU. However, 
elevated levels of Phe and its metabolites can affect also a non-PKU foetus in a 
mother with PKU, if the treatment regime does not eliminate high Phe levels in 
maternal blood during gestation. This situation can cause a condition called 
maternal PKU with severe developmental consequences [Guttler et al., 1999; 
Levy and Ghavami 1996].  
 
 
Table 1. Spectrum of the types of PAH variations according to Human Gene Mutation 
database as of August 2019 (http://www.hgmd.cf.ac.uk/) [Stenson et al., 2017].  
 
Variation type Total number 
of variations 
Missense/nonsense 650 
Splicing substitutions  127 
Regulatory substitutions  2 
Small deletions 106 
Small insertions/duplications 24 
Small indels 13 
Gross deletions 58 
Gross insertions/duplications 5 
Complex rearrangements 2 
Repeat variations 0 
Total 987 
 
 
2.5. Genotype and prevalence of PKU 
Several geographically distinct populations show high predominance of some 
particular variations or at least a significantly increased ratio of one variant 
compared to the others. Thus, different founder populations of mutant alleles 
must have been existing; the effect of genetic drift is probable. For example, in 
Southern Europe and the Mediterranean area, the c.1066-11G>A variant, which 
introduces an alternative splice acceptor site in intron 9, counts for 10% to 40% 
of all PKU alleles. However in general in Southern European populations there 
is a greater heterogeneity in PAH variations than in Eastern Europe [Couce et 
al., 2013; Desviat et al., 1999; Ozguc et al., 1993; Rivera et al., 1998; Zschocke 
2003], similar to the situation that exists in Latin America [Perez et al., 1993].  
In Eastern Europe, p.Arg408Trp variation is highly predominant, forming a 
North-South gradient: up to 56% in Moscow region [Charikova et al., 1993],  
62–65% in Poland [Bik-Multanowski et al., 2013; Kalaydjieva et al., 1991], 
73.5% in Lithuania [Kasnauskiene et al., 2003], 51% in Russia [Gundorova et 
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al., 2019], 38% in Romania [Gemperle-Britschgi et al., 2016], 18% in Serbia 
and Montenegro [Stojiljkovic et al., 2006]. Historically, single nucleotide poly-
morphisms (SNPs) leading to detection of restriction fragment length poly-
morphisms (RFLPs), a variable number tandem repeat (VNTR) motif and a 
short tandem repeat (STR) polymorphism variations have been useful to create 
haplotypes in the PAH gene to trace the origins of variations and diagnostic 
properties [Goltsov et al., 1992; Goltsov et al., 1993; Woo 1988]. The previous-
ly mentioned variation p.Arg408Trp is widely present on a different VNTR/ 
STR haplotype background in Ireland – 43% [Eisensmith et al., 1995], probably 
referring to independent recurrence in human history [Tighe et al., 2003]. This 
p.Arg408Trp variation is much less frequent in the Mediterranean area – about 
4% [Berthelon et al., 1991]. East-European structure of PAH variations has 
been reported also from the Far-East of Russia (Pacific region), wherein 
p.Arg408Trp accounts for 63% of pathogenic variations [Sueoka et al., 1999]. 
The p.Arg408Trp variation fully abolishes PAH activity, resulting in severe 
PKU phenotype, if homozygous. The highly conserved Arg-408 is located on 
the hinge loop that connects the tetramerisation arm to the core of the PAH 
monomer (Figure 2) [Fusetti et al., 1998].  
For Northern Europe, c.1315+1G>A is typical, especially for Denmark, 
which has been considered to be the founder population, with relative frequency 
of 45% among all PKU alleles [Eisensmith and Woo 1994]. Later studies have 
revealed a somewhat lower, but still outstanding, prevalence of c.1315+1G>A 
in Denmark (Table 2). In Switzerland and Turkey, p.Arg261Gln is relatively 
frequent: 32% and 10% of affected alleles, respectively [Eisensmith et al., 
1992], as well as 9% in Sicily [Mirisola et al., 2001] and 10% in Portugal 
[Rivera et al., 1998]. Variation p.Arg158Gln is present in most populations, but 
no study has shown to contain it in a significantly higher percentage. Certain 
populations have specific mutations characteristic almost entirely to them, such 
as the Yemenite Jews, who carry a deletion of the whole exon 3 [Avigad et al., 
1990]. Roma of Eastern Europe often carry the p.Arg252Trp allele [Kalanin et 
al., 1994]. Several less frequent mutations are distributed sporadically. The 
populations derived from various origins of migration (e.g. the United States) 
exhibit wide spectra of PAH variations where none of them clearly dominates 
over the others in frequency [Guldberg et al., 1996]. As expected, different and 
variable genotypic structure is present in China, wherein the p.Arg243Gln allele 
is the most prevalent mutation, with a relative frequency of 20% [Li et al., 2018; 
Wang et al., 2018]. The phenomenon of extreme PKU frequency among the 
Karachay people in North Caucasus exists with widespread prevalence of the 
p.Arg261* variant present in 68% of their PKU alleles [Gundorova et al., 2018]. 
In general, variations common in Caucasoid populations show very low fre-
quency among Asian peoples, e.g. China and Japan, and vice versa. 
Many populations with increased PKU incidence are present in Europe 
ranging from 1 in 3000 to 1 in 35,000 [Loeber 2007]. In Asians, the incidence 
has been shown to be lower – 1 in 20,000 in China [Chen et al., 2018], 1 in 
53,000 in Japan [Yamaguchi-Kabata et al., 2019]; but 1 in 4370 live births in 
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Turkey [Ozguc et al., 1993]. Other frequencies include 1 in 5300 in Ireland, 1 in 
7700 in Poland, 1 in 9000 in Czechia [Kozak et al., 1997], 1 in 12,000 in 
Portugal [Rivera et al., 1998], 1 in 16,700 in Italy, 1 in 13,000 in France, and 1 
in 15,800 in Sweden [Ohlsson et al., 2017]. Our neighbours in Latvia have the 
incidence 1 in 8170 [Pronina et al., 2003]. Probably the highest frequency of 
PKU in the world can be found in the North-Caucasian Karachay-Cherkess 
Republic in the Russian Federation (1 in 850 newborns) and 1 in 332 among the 
titular nation of the Karachays, due to the tradition of monoethnic marriages, 
causing decreased genetic variability in those populations [Gundorova et al., 
2018]. On the contrary, the prevalence among the population originating from 
Sub-Saharan Africa shows a difference of an order of magnitude lower fre-
quency than in Caucasoid populations [Hardelid et al., 2008]. 
Estonian neighbourhood populations exhibit two different geographical 
gradients. Eastern-European countries with Baltic and Slavic background have a 
general incidence of PKU approximately between 1:6000 to 1:10,000, with a 
clear predominance of the variation p.Arg408Trp accounting for 50% to 80% of 
all PKU alleles in the population. In the North-West direction, over the Baltic 
sea, the same variation has much lower influence: 14% – 17%, while the 
“Nordic” variation c.1315+1G>A is responsible for 10% – 26% PAH deficient 
alleles. PKU incidence in the Nordic/Scandinavian countries is somewhat lower 
than in the East European populations, one in 12,000 to 14,000 newborns. As an 
outstanding exception, the ethnically close Finnish population has PKU 
incidence lower than 1 in 100,000 [Guldberg et al., 1995]. An overview of PAH 
variations in different populations with focus on variations present in Estonia is 
presented in Table 2. 
It seems curious that a number of different PAH gene variations have be-
come prevalent in various populations. The founder effect and genetic drift are 
obvious in case of common wide-spread mutations [Eisensmith and Woo 1994]. 
Selection in favour of the heterozygotes for the defective PAH gene can be 
proposed [Woo 1989], but no confirmed evidence about the mechanism that 
might bring profit to the carrier is known yet. At least in Ireland and Scotland 
women heterozygous for PKU have been shown to have had fewer pregnancies 
ended in spontaneous abortion, resulting in 7.4% more live-born offspring 
[Woolf 1994]. A hypothesis has been risen that slight HPA in the pregnant 
heterozygote can protect the foetus against abortifacient mycotoxin (ochratoxin 
A) found in stored grain infected by moulds from several species of Aspergillus 
and Penicillum. This might have been an advantage during lean years or hunger 
[Woolf 1986]. Possible over-dominant selection in PKU carriers may have 
occurred predominantly during periods of epidemics or famine [Krawczak and 
Zschocke 2003]. However, there have been numerous independent mutation 
events for PKU in Europe, and several variations have independently recurred 
in different founders and subsequently effectively spread over populations 
[Zschocke 2003].  
The distribution of the phenotypic variations of PKU is in accordance with 
the incidences of the prevalent PAH gene variations with different influences on 
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the reduction of the enzymatic activity of PAH. A specific North-South gradient 
in Europe can be observed, while milder forms of HPA become more frequent 
towards Southern Europe, and severely disabled PAH activity is characteristic 
to Northern and Eastern Europe [Desviat et al., 1999; Zschocke 2003]. Variabi-
lity in the severity of the disorder suggests that different mutations influence the 
phenotypic outcome in different ways. Evidence from in vitro expression 
analysis supports this opinion [Danecka et al., 2015; Okano et al., 1991]. 
 
 
2.6. Defects of biopterin metabolism 
Deficiencies in the synthesis or regeneration system of BH4, the cofactor in 
aromatic amino acid hydroxylation reactions, are rare in all populations. The 
estimated incidence of BH4 deficiencies is 1–2 % of all patients with HPA 
detected by the newborn screening [Blau et al., 2011; Dhondt 2010; Opladen et 
al., 2012]. Current knowledge can be retrieved from the International Database 
of Tetrahydrobiopterin Deficiencies (http://www.biopku.org/biodef/) [Opladen 
et al., 2012]: 303 cases of DHPR deficiency, 37 with GTPCH deficiency, 735 
with PTS deficiency, 55 with sepiapterin reductase (SR) deficiency, and  
30 PCBD deficiency cases have been recorded. The severity of BH4 disorders 
can vary widely, however, BH4 disorders are considered among treatable IMDs. 
The therapies depend highly on the particular molecular lesion, from BH4 
monotherapy in the transient and benign case of HPA, the PCD deficiency, to 
strict low-Phe diet as in severe forms of PKU, together with the substitution of 
neurotransmitter precursors (L-DOPA/carbidopa, 5-hydroxytryptophan (5-HT), 
and folinic acid) in the case of severe DHPR deficiency [Opladen et al., 2012]. 
The therapies may be accompanied with symptomatic treatment such as anti-
convulsive medication for reducing the deleterious effects caused by delay in 
diagnosis and treatment.  
 
 
2.6.1. DHPR deficiency 
DHPR deficiency (OMIM #261630, *612676) is the second most common 
cause of BH4 deficiencies and accounts for about one-third of all forms of BH4 
deficiencies [Blau 2016]. The DHPR enzyme is encoded by the quinoid 
dihydropteridine reductase (QDPR) gene. The QDPR cDNA is 1.2 kb long and 
has been mapped to chromosome locus 4p15.3 [Dahl et al., 1987; Lockyer et 
al., 1987]. It encodes for a protein of 244 amino acids, active as a homodimer. 
The gene extends over more than 20 kb and the coding sequence consists of  
732 bp. QDPR includes at least seven exons ranging within 84–564 bp and six 
introns within a range of approximately 1.7–10 kb. The intron–exon boundaries 
are flanked by canonic splice junctions [Dianzani et al., 1998]. Biallelic patho-
genic variants in QDPR gene lead to BH4-deficient HPA, accompanied with a 
severe biogenic amines deficiency. According to the online register of BH4 
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deficiencies (http://www.biopku.org/biodef/BIODEF) [Opladen et al., 2012], 
303 cases of DHPR deficiency have been recorded. The QDPR locus-specific 
database PNDdb (http://www.biopku.org/home/pnddb.asp) tabulates informa-
tion of 85 disease-causing QDPR variants: 50 of them missense, 8 nonsense,  
8 small deletions, 7 splice variants, 6 small insertions/duplication, 4 indels,  
1 large deletion and 1 synonymous variant. One intronic variant resulting in 
cryptic splice site activation has been reported in a patient with DHPR defi-
ciency [Ikeda et al., 1997]. 
The patients with DHPR deficiency exhibit the elevation of Phe as the first 
phenotypic feature, but in contrast to regular PKU children, the low-Phe dietary 
treatment is not sufficient for the reduction of the pathological processes in-
duced by the lack of neurotransmitters due to the inactivation of AAAHs. The 
severity of the clinical picture can vary according to the molecular lesion and 
residual enzyme activity [de Sanctis et al., 2000]. The main symptoms characte-
ristic to untreated or late-diagnosed DHPR deficiency include a cohort of severe 
neurologic symptoms, e.g. axial hypotonia and truncal hypertonia; abnormal 
thermogenesis, seizures, and microcephaly [Dianzani et al., 1998]. 
Individuals with severe DHPR deficiency require treatment with the hydro-
xylated precursors of the deficient neurotransmitters, phenylalanine-restricted 
diet, or substitutive therapy with BH4, besides folinic acid supplementation. 
They display great clinical heterogeneity, similar to that observed in PKU, sug-
gesting that DHPR deficiency may be the result of a wide range of mutations 
[Dianzani et al., 1998]. However, the treatment of DHPR deficiency differs 
from other BH4 deficiencies. In the case of a block in the pathway of BH4 bio-
synthesis, substitution with the synthetic coenzyme can provide a reservoir for 
several cycles of oxidation and subsequent regeneration to enable aromatic 
amino acid hydroxylases perform their function. In case of DHPR deficiency, 
however, the molecule cannot be regenerated and is used only once, and effec-
tive doses of BH4 should be considerably higher. However, responsive cases of 
DHPR-deficient patients supplemented only with BH4 have been reported 
[Coughlin et al., 2013; Kaufman et al., 1982]. 
 
 
2.6.2. GTPCH deficiency 
GTPCH (EC 3.5.4.16) is the first and rate-limiting enzyme in BH4 biosynthesis, 
catalysing the conversion of GTP into 7,8-DHNP-3'-TP. GTPCH deficiency 
(OMIM *600225, #233910) occurs in autosomal recessive and autosomal domi-
nant forms. This enzyme is encoded by a single GCH1 gene, and the corres-
ponding locus has been mapped to chromosome 14q21–q22.2 [Ichinose et al., 
1994]. The autosomal recessive inherited deficiency of GTPCH is clinically 
characterised by severe neurological symptoms unresponsive to the classic Phe-
low diet [Thony and Blau 1997]. Early replacement therapy with BH4 as well as 
L-dopa/carbidopa and 5-hydroxytryptophan (5-HT) can reduce the symptoms 
significantly [Sato et al., 2014]. 
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The autosomal dominant version of GTPCH deficiency (OMIM #128230) is 
known also as Segawa syndrome or DOPA-responsive dystonia. During the first 
two decades of life, typically segmental or generalized dystonia occurs, and the 
disease may also present as parkinsonism that manifests as rigidity, bradykine-
sia and postural tremor. This condition is treatable with lifelong administration 
of L-DOPA/carbidopa and does not manifest with highly elevated Phe levels 
[Wijemanne and Jankovic 2015].  
 
 
2.6.3. PTS deficiency 
The most common deviation in BH4 metabolism occurs due to abnormalities in 
PTS, 6-pyruvoyl-tetrahydropterin synthase (EC 4.6.1.10), which is encoded by 
a single PTS gene (OMIM *612719) and the corresponding locus has been 
mapped to chromosome 11q22.3–q23.3 [Thony et al., 1994]. Similarly to 
GTPCH deficiency, PTS deficiency is inherited autosomal-recessively and 
develops severe neurological symptoms that are unresponsive to the classic 
low-Phe diet. In contrast to GTPCH deficiency, PTPS deficiency is a more 
heterogeneous condition of HPA, occurring in mild, severe, or intermediate 
forms [Ponzone et al., 1990]. The heterozygotes for deficient PTS are clinically 
normal [Thony and Blau 1997]. 
 
 
2.6.4. PCBD deficiency 
HPA due to PCBD deficiency (OMIM #264070) is caused by homozygous or 
compound heterozygous mutation in the PCBD1 gene, which encodes the 
enzyme pterin-4-alpha-carbinolamine dehydratase (OMIM *126090; EC 
4.2.1.96), and which is located onchromosome 10q22. This enzyme is involved 
in the salvage pathway for BH4. PCBD deficiency is an autosomal recessive 
disorder characterized by mild transient HPA, often detected by newborn 
screening. Patients also show increased excretion of 7-biopterin. Affected indi-
viduals are asymptomatic and show normal psychomotor development, 
although transient neurologic deficits in infancy have been reported [Thony et 
al., 1998a]. This disorder is known also as primapterinuria, and is considered a 
transient and benign form of HPA [Thony et al., 1998b].  
 
 
2.6.5. SR deficiency 
Sepiapterin reductase (SR, 7,8-dihydrobiopterin:NADP+ oxidoreductase; EC 
1.1.1.153; OMIM *182125), belongs to a group of enzymes called aldo-keto 
reductases and is encoded by a gene at chromosome locus 2p13.2. SR catalyzes 
the NADPH-dependent reduction of various carbonyl substances, including 
derivatives of pteridines. Its deficiency (OMIM #612716) manifests in affected 
individuals as an L-DOPA-responsive, diurnally fluctuating movement disorder, 
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usually associated with cognitive delay and severe neurologic dysfunction 
[Bonafe et al., 2001]. Thus, this disorder has been diagnosed also as a DOPA-
responsive dystonia. Patients with SR deficiency do not exhibit clear permanent 
HPA. Other signs of SR deficiency that are observed in some patients include 
parkinsonism, tremor, dysarthria, limb hypertonia, hyperreflexia, psychiatric 
disorders, autonomic dysfunction, and sleep disturbances [Wijemanne and 
Jankovic 2015]. 
 
2.6.6. DNAJC12 deficiency  
Correct folding of aromatic amino acid hydroxylases, including PAH, depends 
on certain molecular chaperones, belonging to heat shock protein (HSP) 
families of 40 and 70 kD molecular weight. Variants in DNAJC12 (OMIM 
#617384, DnaJ heat shock protein family (Hsp40) member C12) were recently 
described to lead to mild HPA, central biogenic amines deficiency, dystonia, 
intellectual disability and parkinsonism, thereby defining a new entity of HPA 
without PAH or BH4 deficiency [Anikster et al., 2017]. DNAJC12 is a member 
of the HSP40 family that has been shown to interact with the aromatic amino 
acid hydroxylases PAH, TYH and TPHs. DNAJC12 binds to PAH through its 
peptide-binding domain and interacts with the HSP70-ATP complex through 
the HPD motif (a conserved His, Pro, Asp signature, crucial for stimulation of 
HSP70’s ATPase activity) in the N-terminal J domain [Blau et al., 2018]. The 
cases with deficient DNAJC12 have been treated by substitution with BH4 
and/or neurotransmitter precursors L-DOPA/carbidopa and 5-HT, which have 
shown beneficial effects, resulting in the prevention of neurodevelopmental 
delay in individuals treated before the onset of symptoms [van Spronsen et al., 
2017a]. 
 
 
2.7. Phenotypes of PAH deficiency  
Normal blood phenylalanine concentration is considered to be 58 +/- 15 μmol/L 
in adults [Cleary and Walter 2001], 60 +/- 13 μmol/L in teenagers and  
62 +/- 18 μmol/L in childhood. In healthy infants and children up to the age of 
18 years, reference blood phenylalanine concentrations are between 21 and  
137 μmol/L, and in adults, 35 to 85 μmol/L [Cleary et al., 2013]. 
The PAH deficiency trait is heterogeneous at the biochemical level with a 
continuum of metabolic phenotypes. It is usually classified as mild, moderate, 
or severe (also referred to as classic) PKU. This classification is commonly 
based on the highest untreated blood phenylalanine concentration following a 
clinical diagnosis or at newborn screening [van Spronsen et al., 2017b]. In 
1980, for the first time, blood Phe levels were used to discriminate between 
three different phenotypes of PKU [Guttler 1980]. Classic PKU was defined by 
presenting with Phe pre-treatment levels >1200 μmol/L, variant PKU with Phe 
pre-treatment levels of 600–1200 μmol/L, and mild HPA with Phe pre-treat-
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ment levels <600 μmol/L. More precisely, PAH deficiency has been classified 
into four different phenotypes: classic PKU presenting with Phe pre-treatment 
levels >1200 μmol/L, moderate PKU with Phe pre-treatment levels of 900– 
1200 μmol/L, mild PKU with Phe pre-treatment levels of 600–900 μmol/L, and 
mild HPA with Phe pre-treatment level <600 μmol/L [Blau et al., 2011; Guld-
berg et al., 1998].  
In practice, classification of PKU is essential for choosing the optimal treat-
ment. Therefore a simplified classification scheme recommended in the Euro-
pean guidelines on phenylketonuria [van Wegberg et al., 2017] is based on 
treatment requirements: a) patients who do need strict dietary treatment (PKU), 
b) patients who do not need any treatment (non-PKU HPA), and c) patients who 
may be treated with BH4 (BH4-responsive PKU) [Blau et al., 2011].  
PKU always causes HPA, but not all HPA is PKU. In the 1970s, several 
children with HPA but unresponsive to dietary Phe restriction (“atypical” or 
“malignant” PKU), with developmental delay and neurological pathology, were 
described [Blau 2016; Cederbaum 1979; Danks et al., 1979]. These cases were 
further identified as BH4 deficiencies, referring to disturbances in BH4 synthesis 
and regeneration.  
It is important not to confuse BH4-responsive PKU and BH4 deficiencies; the 
first ones are a subtype of PAH deficiency, which can be alleviated by supple-
mentation with BH4 and are caused by a number of variations in PAH gene. 
BH4 works as a chaperon and supplementation in excess provides the PAH 
tetrameric protein better opportunities to regain its correct conformation and 
therefore also to restore its enzymatic activity. BH4 deficiencies are caused by 
abnormalities in the synthesis or regeneration of the cofactor, and in these cases, 
elevated Phe is just one of the detrimental changes in the homeostasis of the 
organism. The even more serious changes include the malfunction of TYH and 
TPH as well as NOS, thereby disturbing much of the synthesis of basic compo-
nents of neurotransmission like dopamine, noradrenaline, serotonin and nitric 
oxide and usually leading to more severe clinical phenotype than PKU, if 
untreated.  
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2.8. Diagnosis of PKU 
Ever since the fundamental discovery by Dr Asbjørn Følling in 1934  of phenyl-
pyruvic acid in the urine of mentally handicapped patients (further developed 
into the so-called urinary Følling test with FeCl3) [Centerwall et al., 1960], and 
the success of dietary low-Phe therapy to alleviate the symptoms of a PKU 
patient by German doctor Horst Bickel in 1953,  the importance of diagnosis 
and early treatment of PKU has become the cornerstone of providing life 
quality for individuals with this inborn error of metabolism (IEM). Therefore, 
PKU became the first IEM for newborn screening programmes. The first suc-
cessful screening method was introduced by Guthrie and Susi in 1963, who 
gathered blood samples on filter paper cards (nowadays, the well-known 
“Guthrie cards”). If a large amount of Phe were in the blood, it would overcome 
the metabolic block of a poison (β-2-thienylalanine) that would have otherwise 
inhibited the growth of a certain strain of Bacillus subtilis. The growth zones of 
the bacteria on agarose plates would indicate that the blood spot had an elevated 
Phe level [Guthrie and Susi 1963]. This enabled a technician to perform 
hundreds of screenings a day with very small amounts of blood, rather than the 
urine needed for the ferric chloride test [Zhu 2017]. 
Further, the fluorometric assay by McCaman and Robins, using quantitative 
fluorescence-based measuring of a ninhydrin-phenylalanine complex enhanced 
by L-leucyl-L-alanine dipeptide, later became available and with modifications, 
became widespread for newborn screening [McCaman and Robins 1962; Wu et 
al., 1979]. Together with the advancement of the availability of tandem MS/MS 
for public health care, multiple centres have now extended their newborn 
screening programmes, including multiple other metabolic disorders together 
with PKU [Bodamer et al., 2007]. This strategy has been used in Estonia since 
2014 [Reinson et al., 2018]. 
In general, screening is performed mostly between the ages of 3 and 5 days, 
depending on the logistic capabilities employed in each newborn screening 
programme. A commonly used Phe cut-off level for diagnosis of PKU is 120–
130 μmol/L (with a Phe/Tyr ratio > 2) with MS/MS employed [Blau et al., 
2011]. In Estonia, according to the national PKU treatment guidelines, the cut-
off level of Phe in newborn screening is 3 mg/l (180 μmol/L) [Uudelepp et al., 
2012].  
Currently, molecular diagnosis for finding the causative variants in the PAH 
gene has become an essential part of the diagnostic procedure of any person 
with the manifestation of HPA. This provides also early insight into the options 
and potential responses to treatment [Zschocke et al., 2008; Zschocke et al., 
2012]. 
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2.9. Treatment of PKU 
The main and prevalent therapy for eliminating the hazardous effects of excess 
Phe on the nervous system has been the reduction of ingested natural proteins, 
substituting the lack of this essential nutritional compound with specifically 
designed amino acid mixtures devoid of Phe [MacDonald et al., 2011]. How-
ever, maintaining the recommended Phe levels (see Table 3) by diet may be-
come a burden for an individual with PKU and his/her family. Therefore, efforts 
are being made to find solutions to alleviate the constant restrictions associated 
with the dietary therapy.  
To date, three main different types of treatment are available and more are 
under development to lower the Phe level and keep it in the recommended 
range. The first and most important is the restriction of dietary Phe, which re-
mains the mainstay of PKU management, and which usually begins immedia-
tely after confirmation of HPA in a neonate. Patients with PKU have to accept 
the Phe-free formula for covering the essential need for all other nutritional 
amino acids and to avoid foods rich in protein [Blau et al., 2010]. In contrast to 
earlier suggestions that dietary treatment may be terminated after the most 
vulnerable period of fast brain development and myelin stabilization, there has 
in recent decades been a strong urge toward a strict “diet for life” [Levy and 
Waisbren 1994]. Blood Phe levels in all patients are recommended to be main-
tained in the range of 120–360 µmol/l, with alleviation up to 600 µmol/l in 
adolescents and grown-ups, according to different national guidelines (see 
section 2.10).  
Currently, monotherapy (low Phe diet) or, increasingly, a combination of 
two therapies – either low Phe diet and chaperone (BH4) supplementation 
therapy or low Phe diet and enzyme substitution therapy – is used to control the 
blood Phe level of a given patient. Currently available drug therapy is infre-
quently used to allow for the discontinuation of the low Phe diet [Lichter-
Konecki and Vockley 2019].  
The second important treatment method is the dietary supplementation with 
BH4, as a natural chaperon restoring PAH activity besides being an essential 
cofactor for PAH [Kure et al., 1999; Muntau et al., 2014]. BH4 supplementation 
has become one preferred option since 2007, when sapropterin dihydrochloride 
(the pharmaceutically used version of BH4) became commercially available and 
legally accepted under the name Kuvan TM [Levy et al., 2007]. However, this 
type of therapy is very dependent on the particular genotype of the patient and 
is effective only for a certain fraction of all patients [Burton et al., 2007], main-
ly those with milder phenotypes of PKU [Muntau et al., 2002]. PAH variation 
analysis together with BH4 loading test enable one to predict the type of therapy 
to be recommended to each individual patient [Anjema et al., 2013]. Substantial 
research for getting the spectra of PAH enzyme activities in the presence of 
variable amounts of BH4 cofactor and Phe substrate in 30 frequent homozygous 
and compound heterozygous genotypes has been performed to find possible 
personalised treatment regimens [Danecka et al., 2015]. Thus, the structure of 
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genotypic variability in each particular population may help to predict the most 
efficacious form of therapy to be recommended. For example, approximately 
only 8–10% of Polish patients with HPA may derive possibly benefit from the 
BH4 treatment [Bik-Multanowski et al., 2013], while in Russia, genotype-based 
prediction proposes 20% of PKU patients as potential responders [Gundorova et 
al., 2019]. Responsiveness to BH4 is predictably much higher (>75%) in 
Southern regions of Europe with a high frequency of BH4-responsive alleles 
p.Arg261Gln, p.Val388Met, p.Ile65Thr, p.Arg158Gln, or p.Leu48Ser, than in 
Central Europe (50–70%), or in some Eastern European countries (<40%) with 
frequent severe alleles like p.Arg408Trp, p.Arg252Trp, or c.1315+1G>A 
[Zurfluh et al., 2008]. 
The third treatment option for alleviating the damage caused by excess Phe 
in CNS is the enrichment of the diet with LNAAs, which compete with Phe for 
the same transporter protein through BBB [Pietz et al., 1999] and thus reducing 
the concentration of Phe in the brain [Moats et al., 2003]. However, this method 
cannot be considered as monotherapy. 
Combined therapy of low-Phe diet, LNAA and BH4 supplementation has 
been considered in responding patients to relieve the possible burden of dietary 
restriction [Yano et al., 2016].  
Currently, active development is being conducted on enzyme substitution 
therapy with phenylalanine ammonia lyase (PAL, pegvaliase, EC 4.3.1.5), an 
enzyme that degrades Phe via a different pathway than PAH. This therapy holds 
promise as a non-dietary way to control the Phe level in PKU. PAL is a non-
mammalian enzyme that converts Phe to trans-cinnamic acid and ammonia. 
Clinical trials with injected pegvaliase have shown effect on lowering Phe 
levels in adult PKU patients [Harding et al., 2018]. Engineered versions of 
pegvaliase with attached polyethylene glycol (PEG) molecules to stabilize and 
protect the PAL protein in the intestine have now been approved in the United 
States under the name Palynziq™ as an enzyme substitution therapy for PKU 
[Levy et al., 2018] for adults with blood Phe levels ≥600 μM. In April, 2019, 
this treatment approach was approved for adolescent adults of >16 years of age 
by the European Medicines Agency [Grisch-Chan et al., 2019]. Variable 
methods of PAL administration both as cellular insertions and in cell-free units 
are in rapid progress. 
A natural source of low-Phe protein called glycomacropeptide (GMP) is also 
available as a dietary supplement, which has an extraordinarily low level of Phe 
(2.5–5 mg Phe/g protein). GMP is a 63 amino acid C-terminal part of kappa-
casein which is released in whey during cheese making by the action of 
chymosin [Neelima et al., 2013]. A variety of foods and beverages can be made 
with GMP to improve the taste, variety and convenience of the PKU diet [Ney 
et al., 2009].  
For studying increasingly developing treatment variations for PKU, the 
creation of a mouse model Pahenu2/2 was published by McDonald almost 30 
years ago [McDonald et al., 1990]. This model is often used for viral vector 
based gene therapy experiments targeting mainly hepatocytes. More than a 
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dozen different attempts of such gene therapy on Pahenu2/2 mouse model have 
been performed, with several promising outcomes [Grisch-Chan et al., 2019]. 
The most widespread genome editing tool, the CRISPR/Cas9 system, enables 
editing particular point mutations, but has raised safety concerns, especially due 
to the existence of other known therapies without these threats of unknown 
safety.  
The U.S. PKU guidelines state (in the “Future Directions” section), that new 
therapies, including gene therapy and hepatocyte transplant, have shown some 
efficacy in animal or limited human trials but require further development and 
validation for routine clinical use [Vockley et al., 2014]. However, the recent 
European guidelines for PKU mention dietary and enzyme replacement therapy 
but not gene therapy as an option [van Spronsen et al., 2017b]. 
 
 
2.10. Dietary recommendations for PKU  
Since the first observations made in 1953 [Bickel et al., 1953], dietary manage-
ment of PKU has remained the main intervention to achieve proper develop-
ment of the affected individuals. Much effort has been made to provide well-
balanced nutritional formulae to substitute the restriction of proteins from diet 
[MacDonald et al., 2011]. Consensus for continuing the diet indefinitely has 
been agreed for 25 years already [Council 1993]. It has been shown, that the IQ 
levels in PKU patients are dependent on the strictness of the diet from birth to 
12 years of age, and not as significantly afterwards [Pietz et al., 1998]. How-
ever, limiting the exposure to high levels of Phe after that age may help 
avoiding various neurological problems and may have additional benefits for 
the medical and cognitive status of these individuals [Koch et al., 2002]. Uni-
fied improved (international) guidelines for PKU, both for treatment of 
children, but also after childhood, should address additionally the nutritional, 
neuropsychological and psychosocial issues and focus not only on plasma Phe 
concentrations [van Spronsen and Burgard 2008]. The national guidelines vary 
significantly among nations for the recommended upper Phe values for follow-
up of the adherence to low-Phe diet as well as for the constitution of the age 
groups for each recommended value [Demirkol et al., 2011]. 
 
 
2.10.1. European guidelines 
In 2017, after substantial amount of work, a group of experts reached a con-
sensus and published European guidelines for the diagnosis and management of 
patients with PKU [van Spronsen et al., 2017b; van Wegberg et al., 2017]. 
Low-Phe diet is the cornerstone of treatment, although some patients can 
benefit from tetrahydrobiopterin (BH4). No intervention is required if the blood 
phenylalanine concentration is less than 360 μmol/L. Treatment is recom-
mended up to the age of 12 years if the phenylalanine blood concentration is 
34 
between 360 μmol/L and 600 μmol/L, and lifelong treatment is recommended if 
the concentration is more than 600 μmol/L (Table 3). For women trying to con-
ceive and during pregnancy (to avoid maternal PKU), untreated phenylalanine 
blood concentrations of more than 360 μmol/L need to be reduced. Treatment 
target concentrations are as follows: 120–360 μmol/L for individuals aged 0–12 
years and for maternal PKU, and 120–600 μmol/L for non-pregnant individuals 
older than 12 years. Minimum requirements for the management and follow-up 
of patients with PKU are scheduled according to age, adherence to treatment, 
and clinical status. Nutritional, clinical, and biochemical follow-up is necessary 
for all patients, regardless of therapy [van Spronsen et al., 2017b].  
 
 
2.10.2. Estonian guidelines 
National guidelines for treatment, diagnostics and management of PKU were 
approved in Estonia already in 2012 [Uudelepp et al., 2012]. In comparison 
with the European guidelines, the Estonian recommendations differ mainly by 
being stricter during the first year of life, with a higher Phe value of 240 μmol/L 
allowed. The level of 240 μmol/L is desirable up to 12 years of age, but 360 
μmol/L is considered maximum allowed level. After 12 years, 600 μmol/L is 
considered sufficient (Table 3). The recommendations urge the dietary treat-
ment to be initiated before the 21st day of life to obtain the best outcome, but no 
later than eight weeks of life.  Lifelong treatment is a goal, but minimal duration 
of the dietary treatment should be up to twelve years. Older patients with 
discontinued diet are encouraged to re-start with it, no matter if they have been 
treated since infancy or are late-diagnosed. Women of fertile age are recom-
mended to maintain blood Phe levels below 240 μmol/L already 1 to 3 months 
before conception and keep it below 360 μmol/L during the whole pregnancy.  
 
 
2.10.3. USA guidelines 
In the USA, the recommendations of the NIH Consensus Development Con-
ference (US Department of Health and Human Services, Public Health Service, 
NIH, NICHD, 2001) are to maintain blood Phe between 120 and 360 µmol/L up 
to age 12 and below 900 µmol/L for non-pregnant adults and adolescents. It is 
clear that excess Phe is highly detrimental to brain development prior to 10 
years of age. Limiting exposure to high levels after that age may have additional 
benefits for the medical and cognitive status of these individuals. In light of 
findings that Phe levels are related to cognitive function in adolescents and 
adults, it is recommended that Phe levels be maintained between 120 and  
900 µmol/L after 12 years of age. Considering the fact that brain development 
continues during adolescence, even lower Phe levels (120–600 µmol/L) are 
strongly encouraged during adolescence [National Institutes of Health Con-
sensus Development 2001]. 
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Still, in the USA the recommendations have been varying about the need and 
adherence to therapy according to local policies of different treatment centres. 
The more up-to-date guidelines have come to the conclusion, that treatment for 
PAH deficiency should be lifelong for patients with untreated Phe levels above 
360 µmol/l and maintaining a treated Phe level of 120–360 µmol/L is recom-
mended for all patients of all ages [Vockley et al., 2014]. 
 
2.11. Summary of the literature  
In summary, PKU together with other HPAs is one of the most well studied 
IMDs, and is still providing vast opportunities for research. These opportunities 
rise from the variability between phenotypes, the expanding number of causa-
tive genetic variations, the wide and variable distribution among populations, as 
well as intensive studies towards better management of dietary therapy and 
combinations with cofactor substitution therapy as well as other emerging 
treatment methods. This keeps PKU with other HPAs as a constant hotspot for 
diagnostic, epidemiological, molecular and therapeutic research. Understanding 
the molecular lesions of each particular individual as well as distribution of 
pathological variants among populations provides an important informational 
clue for finding the best possible options for the treatment of each individual as 
well as screening, diagnosis and treatment decisions for clinical practice and the 
whole healthcare system. While making decisions for choosing between 
existing and emerging therapies, the follow-up of blood Phe values in accor-
dance with national guidelines remains the key indicator in the assessment of 
the efficacy of the therapy as well as the ability of each patient/family to adhere 
to recommendations in cooperation with clinical geneticists and nutritional 
therapists.    
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3. AIMS OF THE PRESENT STUDY  
The aims of the present study were: 
1. To establish the genotypes of Estonian patients with hyperphenylalaninaemia 
and correlate these with their phenotypes (Papers I and II);  
2. To compare the spectrum of PAH gene variations among distinct ethnic 
groups in Estonia (Papers I and II); 
3. To assess the geographical distribution of the most prevalent variant 
p.Arg408Trp in the PAH gene (Papers I and II); 
4. To investigate the adherence of dietary therapy among Estonian PKU 
patients (Paper III); 
5. To disclose the molecular lesion underlying the pathogenic status of an 
Estonian patient with DHPR deficiency (Paper IV). 
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4. MATERIAL AND METHODS 
4.1. Study subjects  
 4.1.1. Patient group of genotype/phenotype study  
(Papers I and II) 
Thirty-four Estonian PKU patients born since 1980 were included into the study 
performed in 1996 (Paper I), providing 68 independent affected chromosomes. 
This made up 87% of the known patients born during this period. Pheno-
typically, all patients expressed the ‘classic’ or severe PKU phenotype ac-
cording to the pre-treatment Phe level or Phe tolerance in diet. In Estonia, the 
exact measurement of serum Phe concentration became available since 1992. 
Therefore, the previous patients’ clinical subtype was determined by the physi-
cian only.  
Out of the 34 analysed families, 20 were of Estonian origin not less than 
within two generations, six families were of Slavic (including Russian, Ukrai-
nian, Polish) origin, eight families had at least one ancestor of non-Estonian 
origin, including Russian, Polish, Armenian, and German individuals. 
For the retrospective study of 2018 (Paper II), we created the database of the 
95 available Estonian HPA cases. The case histories of the patients either born 
or living in Estonia since 1974 up to 2016 (43 years) were selected and ana-
lysed. The following information was gathered: family and first name, the year 
of birth, personal ID-code, age at the diagnosis, Phe concentration level at the 
moment of diagnosis, method of diagnosis (either determination of Phe con-
centration fluorometrically, tandem MS/MS in blood or the Følling test from 
urine), highest known Phe concentration value of the particular individual, PAH 
mutation genotype, general remarks about medical condition, data about the 
start and continuation/discontinuation of the treatment, and genealogical data of 
the patient, including information about the ethnicity of the parents and 
grandparents of the proband. Additionally, data about the general medical/social 
status of the person was included into the database.  
The whole cohort was divided into two subgroups according to the year of 
birth: 1974–1992 and 1993–2016, i.e. before and after the initiation of national 
newborn screening programme for PKU.  
 
 
4.1.2. Patient group of phenylalanine measurement study  
(Paper III) 
To analyse the adherence of Estonian PKU patients to the low-Phe diet, we 
created a sub-database of all available entries for the period 2010 to March 2018 
from the general laboratory information management system (LIMS) database. 
LIMS is available for any diagnostic analysis performed in the United Labora-
tories of Tartu University Hospital (UL-TUH), concerning all Estonian patients 
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diagnosed with PKU or other forms of HPA. The created sub-database included 
the following fields: name, personal ID-code, date of sample collection, age at 
the moment of sample collection, assignment to age group at the moment of 
sample collection, Phe value in dried blood spot (either mg/dl or µmol/l), 
genotype, phenotype, time of diagnosis (either from the newborn screening or 
late diagnosis in case of persons born before 1993), and assessment of educa-
tional level. Initially, the database included 4290 entries from 69 patients. How-
ever, as the objective of the study was to acquire insight into the quality and 
proceeding of the ongoing therapy, nine of the subjects and entries concerning 
their blood Phe values were excluded from the database due to some of the 
following reasons: late diagnosis together with severe or profound intellectual 
disability and/or refusal of treatment. The final database for further analysis 
consisted of 4236 entries from 60 patients. 
The following age groups were created: ≤1 year; 1 year 1 day to 2 years;  
2 years 1 day to 6 years; 6 years 1 day to 12 years; 12 years 1 day to 18 years;  
> 18 years (for simplicity further referred to as: 0–1y, 1–2y, 2–6y, 6–12y, 12–
18y, 18+y, respectively). The age group 0–1y contained 662 entries from 19 
patients, 1–2y contained 548 entries from 19 patients, 2–6y contained 1140 
entries from 20 patients, 6–12y contained 470 entries from 19 patients, 12–18y 
contained 477 entries from 16 patients and the adult group 18+y contained 933 
entries from 27 patients. Median, maximum and minimum Phe values were 
counted for each group. All entries with Phe values above the maximum 
recommended value of 360 µmol/l (extrapolated to 6 mg/dl) in cases of patients 
up to 12 years of age and higher than 600 µmol/l (extrapolated to 10 mg/dl) in 
cases of patients older than 12 years of age were counted and the ratio of entries 
elevating the recommended level was calculated.  
 
4.1.3. DHPR patient (Paper IV) 
The proband with DHPR deficiency was born as the first child of unrelated 
Estonian parents following a normal pregnancy with birth weight 3365 g, length 
48 cm and Apgar scores of 8 and 9 at 1 and 5 minutes, respectively. Since the 
first week of life, the proband’s mother noticed muscular rigidity and further 
lack of eye contact. Later permanent constipation, and continuous periods of 
crying with only brief spontaneous laughter were noted. At the age of six months 
she was hospitalised for further investigations due to developmental delay and 
spasticity. On metabolic screening, HPA (plasma Phe = 1179 µmol/L) was 
detected, and a low-Phe diet was started assuming that the child had classical 
PKU. However, she did not improve clinically and seizures started one month 
later. Accordingly, a high suspicion of disturbance in BH4 metabolism arose. At 
the age of 8 months, a Phe loading test (0.1 g Phe/kg body weight) was performed 
at Vilnius Children’s Hospital, Lithuania. This test showed a sharp increase in 
Phe level: at 0 min after consumption – Phe 23.4 µmol/L, Tyr 79.9 µmol/L; at  
65 min – Phe 629.3 µmol/L, Tyr 71.4 µmol/L; at 100 min – Phe 1083 µmol/L, 
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Tyr 91.4 µmol/L). Further, BH4 loading test (7 mg BH4/kg body mass) on the 
background of increased Phe level was performed at the age of 9 months. The 
second loading test showed variable changes in plasma Phe and Tyr: 0 h – Phe 
1400 µmol/L, Tyr 55.8 µmol/L; 4 h – Phe 923.7 µmol/L Tyr 55.8 µmol/L; 8 h – 
Phe 1555.3 µmol/L Tyr 62.8 µmol/L; 24 h – Phe 892.3 µmol/L Tyr  
48.8 µmol/L, indicating possible disturbance in BH4 synthesis/regeneration. 
At the age of 11 months, the child was reinvestigated for BH4 cofactor 
disorders. BH4 loading test, urinary biopterin analysis and CSF neurotransmitter 
analyses showed biochemical abnormalities indicating DHPR deficiency. 
Neopterin in urine was normal: 1.6 mmol/mol creat (normal: 1.1–4.0 mmol/mol 
creat) and biopterin was significantly increased: 12.3 mmol/mol creat (normal: 
0.5–3.0 mmol/mol creat), resulting in elevated percentage of biopterin (88%). 
The BH4 loading test (20 mg/kg body weight) resulted in blood Phe reduction 
from initial 496 µmol/L to 254 µmol/L and, Phe 169 µmol/L, 4 and 8 hours 
after BH4 administration, respectively. Investigation of CSF neurotransmitters 
showed normal neopterin – 18 nmol/L (normal: 9–40 nmol/L) and elevated 
biopterin – 65 nmol/L (normal: 10–50 nmol/L), very low 5-HIAA – 19 nmol/L 
(normal: 114–336 nmol/L) and HVA – 170 nmol/L (normal: 295–932 nmol/L), 
5-MTHF – 26 nmol/L (normal: 64–182 nmol/L), all compatible with DHPR 
deficiency. The diagnosis was confirmed by the absent DHPR activity in dried 
blood (<0.5 µU/g Hb; normal: 2.3–3.8). 
 
4.2. Methods 
4.2.1. Variation analysis in PAH deficient patients 
In the work performed for Paper I, polymerase chain reaction (PCR) was used 
for amplifying PAH gene exons 5, 7, 11 and 12 as the regions of most common 
variations [Eisensmith et al., 1992]. Firstly, variations in these four exons were 
screened. If no results were obtained, other exons were considered. PCR 
primers were chosen using data from reported amplification systems. GoldStar 
Taq DNA polymerase (Eurogentec, Belgium) was used with an appropriate 
buffer system, 33 cycles (94°C for 45 s; 56°C for 1 min; 72 °C for 1 min 30 s) 
were performed. 
Sequence Analysis: Solid-phase sequence analysis was performed by the 
Sanger dideoxychain termination method using the Sequenase™ Version 2.0 
DNA Sequencing Kit (Amersham Life Science) and [35S] α-ATP, according to 
the protocol provided by the manufacturer. One biotin- linked oligonucleotide 
PCR primer was used for preparing the single-stranded probes which were 
bound to streptavidine-coated magnetic beads (Dynabeads® M-280, Dynal 
A.S.) for strand separation. Exons 5, 7 and 12 were sequenced completely, if no 
p.Arg408Trp was found.  
Restriction Analysis: Many of the proposed mutations in the DNA areas 
under research could be analysed by digesting the PCR product with restriction 
endonucleases [Eiken et al., 1991]. Special attention was paid to the 
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p.Arg408Trp variation which is distributed with high frequency in areas geo-
graphically close to Estonia and can be effectively identified by StyI digestion 
[Ivaschenko and Baranov 1993], as it creates a new restriction site in exon 12. 
HinfI, AvaI and BamHI restriction enzymes were used for digestion exon 7 to 
check for probable p.Arg261Gln, p.Arg252Trp, Gly272ter variations according-
ly and DdeI to detect c.1066-11G>A in exon 11 (flanking regions) [Eiken et al., 
1991]. Restriction fragments were analysed by 2.5% agarose gel electrophoresis 
in Tris-borate-EDTA (TBE) buffer. Single-Stranded Conformational Poly-
morphism (SSCP) Analysis: Denatured single-stranded PCR 185- to 295-bp 
products were separated by electrophoresis on homogeneous 12.5% poly-
acrylamide PhastGel® gels using two different temperatures: +4 and +15 °C 
and developed by silver-staining. SSCP was used if previously described 
methods did not reveal the variations.  
Paper II: Variation analysis of the PAH gene of the probands as well as their 
parents, when available, was performed as described above or/and PCR and 
automated dideoxy sequencing with ABI 3130XL capillary sequencer (Applied 
Biosystems) of the PAH gene NM_000277.1 exons (1–13) and exon–intron 
boundaries. The presence of the prevalent p.Arg408Trp variation was checked 
first, if missing, all PAH gene exons were sequenced completely and MLPA 
analysis was performed using commercially available kit SALSA®MLPA® 
Probemix P055-PAH (MRC-Holland). 
 
4.2.2. Measurement of Phe levels 
Two different methods of Phe measurement from dried blood spots (BS) col-
lected on filter paper (Schlieicher and Schuell filter paper No 2992) were used. 
The first used method was the modified McCaman and Robins quantitative 
fluorescence-based assay measuring ninhydrin-phenylalanine complex en-
hanced by L-leucyl-L-alanine dipeptide [Wu et al., 1979] using Labsystems 
neonatal phenylalanine kit (no. 6199 897) and FluoroScanTM (Labsystems Oy, 
Helsinki, Finland) device. Since 2014 we introduced LC-MS/MS tandem mass 
spectrometry on Waters AquityTM Ultra Performance LC device using Chrom-
Systems MassChrom® Amino Acids and Acylcarnitines from Dried Blood kit 
(order nr 55000) applying neutral loss scan 120 detection, according to the 
methods provided by the manufacturer. In 2015, a switch in analytical methods 
from fluorescence measurement to LC-MS/MS analysis occurred. Thus, Phe 
values have been presented in different units. However, in order to unify the 
results, both types of values were converted (by either multiplying or dividing 
by a factor of 60.54, as one Phe unit measured in mg/dl equals to 60.54 µmol/l) 
to obtain comparable numeric values. As the values obtained by FluoroScan 
were not distinguished if lower than 1 mg/dl and higher than 25 mg/dL (shown 
as <1 and >25 mg/dl in the original database, respectively), aforementioned 
values were substituted with 0.9 and 25.1 mg/dl to enable analysis with numeric 
values. For simplicity, and considering the total number of measurements by 
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different methods, Phe values in mg/dl (instead of µmol/l) were used in calcu-
lations. 
 
4.2.3. Assessment of educational level 
Data about the educational level of the PKU patients were obtained during 
regular visits to outpatient clinic from the patients and/or their families. The 
patients younger than 18y of age were assigned as “normal school”, “assisted 
education” or “preschool age”. In the patients older than 18y of age, educational 
levels were evaluated according to ISCED 2011 scaling [Institute for Statistics 
and UNESCO. 2012].  
 
4.2.4. Prevalence estimation 
To estimate the prevalence of PAH-dependent HPA-s in Estonia, the period 
from 1993 to 01.09.2016 was taken under observation. The population data of 
all live births from 1993 to 2015 was obtained from national statistics agency 
Statistics Estonia (http://www.stat.ee). The number of screened newborns 
between 01.01.2016 and 01.09.2016 was added according to the data recorded 
in the screening laboratory of the Department of Clinical Genetics, United 
Laboratories of Tartu University Hospital. The data about all diagnosed HPA 
patients born during the whole period was collected at the Department of 
Clinical Genetics, United Laboratories of Tartu University Hospital.  
 
4.2.5. Statistical analysis  
Statistical analysis of the genealogical data was performed with SAS software 
(SAS® 9.2 Analytics, SAS Institute Inc.). Data collected about the birthplaces 
of the grandparents of PKU patients’ parental linage of Estonian ethnicity and 
carrying the p.Arg408Trp allele (all other mutation linages and ethnicities were 
removed) were determined with the fidelity of county. The analysed dataset 
consisted of 52 multivariate independent observations corresponding to 52 
observed PKU patients. The pool of known localisations contained 162 birth-
places of grandparents. The number of possible carrier grandparents in each of 
the 15 counties of the Republic of Estonia and the pre-World War II Petseri 
County per county was normalised to the population number of each county 
(taking into account the percentage of inhabitants of Estonian ethnicity). 
Population data and administrative structure were selected as of the year 2009 
with the predisposition that demographic tendencies in the window of two 
generations have been similar over the whole country; as an exception data 
from the year 1934 were used for Petseri County now remaining out of the 
administration of the Republic of Estonia. Confidence limits to the results were 
obtained by bootstrap method [Efron 1981]. 
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Knowing the number of Estonians in a county, and the number of registered 
p.Arg408Trp alleles in this county, we calculated the expected number of 
p.Arg408Trp alleles per 10,000 Estonians in the county. To find confidence 
limits for the number of p.Arg408Trp per 10,000 Estonians, we used the B. 
Efron’s estimation approach [Efron 1981]. For this, we replaced the real sample 
for a county with 1000 random samples of the same size as the real sample. 
With each of these 1000 bootstrap samples, we repeated the same calculations 
as with the real sample and calculated 1000 bootstrap estimates for the number 
of known p.Arg408Trp carriers per 10,000 Estonians. Ordering these 1000 
estimates increasingly, we considered the 25th lower estimate as the lower con-
fidence limit (LCL) and the 976th estimate as the upper confidence limit (UCL). 
All data concerning the numbers and locations of Estonian population were 
obtained from official public database Statistics Estonia http://www.stat.ee.  
 
4.2.6. Genealogical survey 
Parents of the PKU patients were requested to fill a questionnaire for genea-
logical search. The questionnaire comprised fields about the names, maiden 
names, birth dates and birthplaces of the parents and grandparents of the PKU 
patients, who had at least one grandparent of Estonian ethnic origin. The birth-
place data were preferably intended to contain information about the village, 
parish and county. Further an illustrative map was created, wherein each birth-
place of a known grandparent carrying the p.Arg408Trp mutation in the PAH 
gene with 50% probability was determined with a spot. In case birthplaces were 
approximate, the spots were located into the centre of respective parish or 
county. Altogether 160 birthplaces of grandparents were available to be located 
to the map.  
 
4.2.7. Variation analysis of the DHPR deficient patient 
In an effort to identify the causative variants for DHPR deficiency, QDPR gene 
NM_000320.2 exons with their flanking regions were Sanger sequenced four 
times by different laboratories in the index patient and her parents.   
 
4.2.8. Exome sequencing of the DHPR patient 
Exome sequencing of index patient was carried out in the Estonian Genome 
Centre at the University of Tartu. DNA library was prepared using Nextera 
Rapid Capture Exome 37 Mb kit (Illumina Inc.) according to the manufacturer’s 
protocols. The HiSeq 2500 (Illumina Inc.) platform was used for paired-end 
2×100 bp sequencing. The bioinformatics data processing made use of BWA 
[Li and Durbin 2009], which mapped the reads to the hg19 reference genome, 
and different Picard (v2.2.2) and Genome Analysis Toolkit (GATK) (v3.5-0) 
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tools to mark duplicate reads, recalibrate base quality scores. GATK Haplotype 
Caller v3.5-0 was used to call variants.  
An in-house variant annotation pipeline was used. Annotations included, but 
were not limited to reference databases from ExAC [Lek et al., 2016] and 1000 
Genomes Project [Genomes Project et al., 2015], and ClinVar pathogenicity 
annotations [Landrum et al., 2016], as well as HPO terms [Kohler et al., 2014] 
and OMIM disorders as gene-based annotations. Additionally, allele counts 
from our in-house database of variants detected among all NGS analyses 
(panels and ES) performed in our department (654 samples) were annotated to 
every detected variant. 
CNVs were called using CoNIFER software [Krumm et al., 2012]. First, 
reads per thousand bases per million reads sequenced (RPKM) values were 
calculated for each sample separately. Second, all available samples using the 
same library preparation kit were joined for CNV calling. CNV detection and 
plot generation for detected CNVs were carried out subsequently according to 
CoNIFER guidelines. 
 
 
4.2.9. mRNA study 
Blood for mRNA analysis was collected from the parents and a control, to 
obtain cDNA from QDPR and analyze the integrity of the cDNA by PCR. PCR 
was performed from the cDNA synthesized from blood extracted RNA (Tem-
pus™ Spin RNA Isolation Kit, incl DNAse treatment) with SuperScriptTM III 
Reverse Transcriptase (Invitrogen) according to the manufacturer’s protocol; 
the first strand cDNA was synthesized using Random Hexamers (Applied Bio-
system). The primers (QDPR_Rev GTGACTTTTCTGGCAGGCCCCTCATA 
and QDPR_For GGAGCTGCGGGAGCCGGGCT) were designed from UTR 
regions of the transcript (NCBI Reference Sequence: NM_000320.3), thus an 
alternative (93 bp) exon was included into the PCR products with predicted 809 
and 716 bp fragments depending on the presence/absence of alternative exon. 
Phusion Hot Start II DNA Polymerase (ThermoFisher) was used for the PCR 
reaction.  
 
4.2.10. Genome sequencing 
Genome sequencing (GS) and data processing were performed by the Genomics 
Platform at the Broad Institute of MIT and Harvard.  PCR-free preparation of 
sample DNA (350 ng input at >2 ng/µl) was accomplished using Illumina 
HiSeq X Ten v2 chemistry. Libraries were sequenced to a mean target coverage 
of >30x.  GS data was processed through a pipeline based on Picard, using base 
quality score recalibration and local realignment at known indels. The BWA 
aligner was used for mapping reads to the human genome build 38. Single 
Nucleotide Variants (SNVs) and insertions/deletions (indels) are jointly called 
across all samples using Genome Analysis Toolkit (GATK) HaplotypeCaller 
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package version 3.4. Default filters were applied to SNV and indel calls using 
the GATK Variant Quality Score Recalibration (VQSR) approach. Annotation 
was performed using Variant Effect Predictor (VEP). Lastly, the variant call set 
was uploaded to Seqr for collaborative analysis between the Center Mendelian 
Genomics and investigator. 
 
 
4.2.11. Validation of possible breakpoint 
To validate the possible inversion we designed oligonucleotide primers (Table 
4) to perform PCR amplification, and subsequent Sanger validation around the 
breakpoints inside exon 2 of QDPR gene and intron 8 of ACOX3 genes. 
 
 
Table 4. PCR primers for validation studies of the breakpoint detected in ACOX3 and 
QDPR genes of the DHPR deficient patient and her family. 
 
ACOX3 
F1 5’-TGCATGAAGACAGTGGAATCA-3’ 
R1 5’-AGGAATCACAGTCTCGTTGT-3’ 
QDPR 
F2 5’-TCATGAAACTGGGGAAAGAGGT-3’ 
R2 5’-AGTTTCGCTTGTCTCCCAGG-3’ 
 
 
4.2.12. Chromosome analysis 
Karyotype analysis from peripheral blood lymphocytes was performed by using 
conventional GTG-banding technique (G-bands by trypsin using Giemsa; band 
level 550). Karyotypes were described according to the International System for 
Human Cytogenetic Nomenclature (ISCN2016), [Gonzalez Garcia and Meza-
Espinoza 2006]. Both karyotypes were performed at the 550-band level.  
 
 
4.3. Ethics 
All activities performed during this study were approved by Research Ethics 
Committee of the University of Tartu (approval date 21.09.2015 number 251/T-
6) and were strictly in accordance with the Declaration of Helsinki. Informed 
consent for carrying out research was obtained from the patients and/or their 
parents/caretakers. The raw data of the patients was maintained only in the 
servers of the Tartu University Hospital and any information made available for 
the public was coded in a manner not enabling linking delicate personal data 
with particular persons.  
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5. RESULTS AND DISCUSSION  
5.1. The genotype of Estonian HPA patients  
5.1.1. The genotype of Estonian HPA patients known  
by 1996 (Paper I) 
In the study from 1996, variations in 63 alleles out of the 68 affected ones (34 
individuals) were identified. In these alleles under study, 57 (84%) were 
detected as defective due to p.Arg408Trp. Twenty four patients were homozy-
gotes for p.Arg408Trp, nine were compound heterozygotes for p.Arg408Trp, 
and only one patient was a compound heterozygote with p.Arg158Gln / 
p.(?)/IVS12+1G>A variations. These data correlate well with Hardy-Weinberg 
equilibrium, providing evidence that the Estonian PKU patient pool is balanced 
and that it is likely that other (milder) forms had not been missed. The other 
identified variations included p.Arg252Trp, p.Arg261Gln, and p.Ser349Pro 
[Lillevali et al., 1996].  
Although the number of samples studied was not very large, it became clear 
that Estonia is one of the most homogeneous countries for the structure of 
mutant PAH alleles. According to data published by 1996, no other population 
displayed such a high frequency (84%) of the p.Arg408Trp variation [Eisen-
smith et al., 1995]. It has been suggested that p.Arg408Trp on the East-Euro-
pean haplotype is of Balto-Slavic origin [Eisensmith and Woo 1994; Kalay-
djieva et al., 1991], or may even originate from more ancient pre-Indo-Euro-
pean people [Giannattasio et al., 1997]. So far, the highest frequency of this 
mutation had been described in Byelorussia, where it was present on 75% of 
mutant alleles [Zekanowski et al., 2001]. 
Linguistically and ethnoculturally, the Estonians belong to the Finno-Ugric 
peoples, and the results of the current study indicate that p.Arg408Trp, as one 
option, may originate from early Finno-Ugric tribes who inhabited large areas 
of Eastern Europe including northwest Russia and the Volga River region. They 
were largely assimilated by Slavic and Baltic tribes and may have donated the 
mutant allele to them, later spreading widely. Another possibility that can 
explain the very high frequency of one mutant allele is genetic drift. Periods 
with decreasing number of inhabitants clearly exist in the history of Estonia, 
most recently in the beginning of the 18th century. In this way, one allele can 
occasionally reach a higher frequency, or in case of proposed over-dominant 
selective advantage, contributed to the survival of the carriers [Krawczak and 
Zschocke 2003]. 
The rest of the identified variations were well known:  p.(?)/IVS12+1G>A 
was detected twice (3%), providing evidence of contacts with Scandinavian 
peoples; alleles with p.Arg261Gln, p.Arg252Trp, and p.Arg158Gln have a 
random distribution in several Caucasoid populations [Eisensmith et al., 1992]. 
Since the Estonian population is rather homogeneous for the p.Arg408Trp 
variation, which is easily detectable by the PCR/ StyI restriction test, this test 
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was introduced as quick and reliable first tier analysis for any newborn iden-
tified in the screening before performing other tests to eliminate BH4 defi-
ciencies. The presence of this affected allele (in homozygous or heterozygous 
state) confirms that the person is a PAH-deficient PKU patient without the need 
for further investigations of the BH4 system. If absent, the BH4 loading test was 
performed as recommended [Dhondt 1991]. 
 
 
5.1.2. The genotype of Estonian HPA patients known by 2016 
(Paper II) 
By 2016, genotype data for 92 PKU probands (out of 94) was available. Two 
patients from the elder cohort have emigrated, one had died and consequently 
data about only one of her alleles exists. In addition, variation analysis of one 
proband (with a mild PKU phenotype) has been successful for only one allele. 
Taken together, we were able to include 182 alleles into the study. Among 
these, sixteen were from siblings of a previously identified proband, while three 
more alleles had to be removed from the list of independent alleles, as the 
families could be genealogically traced back to the same great-grandparent of 
the probands. Accordingly, the known Estonian PAH allele pool contained 153 
independent alleles [Lillevali et al., 2018]. Among these, 123 independent 
alleles were harbouring the p.Arg408Trp variation characteristic to East-Euro-
pean populations, constituting 80.4% of all PKU alleles and thus being one of 
the highest reported prevalence [Tighe et al., 2003]. In general, the distribution 
of this disease-causing allele highly resembles the total genetic structure of 
various European populations obtained by wide-screen analysis of neutral SNP-
s [Nelis et al., 2009]. The detailed results of the pathogenic alleles are presented 
in Table 5.  
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Table 5. PAH variations among PKU patients (N=92) in Estonia (independent alleles) 
[Lillevali et al., 2018]. 
Variation in the PAH gene Number of 
independent 
alleles 
% of all 
independent 
alleles 
ethnic origin 
p.Arg408Trp (c.1222 C > T) 123 80.4% Therein Estonian  – 89   
Slavic – 31                     
Mixed – 3                       
p.Leu48Ser (c.143 T > C) 5 3.3%  
p.(?)/IVS12+1G>A (c.1315 + 1G 
> A) (IVS12+1 G > A) 
4 2.6%  
p.Arg261Gln (c.782 G > A) 3 2%  
p.Arg252Trp (c.754 C > T) 2 <1%  
p.Glu280Lys (c.838 G >A) 2 <1%  
p.Pro281Leu (c.842 C > T) 2 <1%  
p.Ile306Val (c.916 A > G) 2 <1%  
p.Ile65Thr (c.194 T > C) 1 <1%  
p.Arg158Gln (c.473 G > A) 1 <1%  
p.Asp222* (c.663_664 del AG) 1 <1% Armenian 
p.Ala300Ser (c.898 G > T) 1 <1%  
p.Ser349Pro (c.1045 T > C) 1 <1%  
p.Glu390Gly (c.1169 A > G) 1 <1% Georgian 
c.Gln355_Tyr356insGlyLeuGln/ 
IVS10-11G>A c.1066-11G>A 
1 <1% Slavic 
p.Ala403Val (c.1208 C > T) 1 <1% Azerbaijan 
Unknown (not  p.Arg408Trp) 2 1.3%  
Total 153 100%  
 
 
The upgraded analysis of the genetic structure of the Estonian PAH-deficient 
HPA patients revealed sixteen different pathogenic variations in the PAH gene. 
Two more alleles remained unidentified in this gene pool, as the DNA of one 
patient with classical severe PKU phenotype (with p.Arg408Trp in one allele) 
was not available anymore, and in another patient with a mild phenotype, we 
were not able to identify the pathogenic variation (beside p.Arg408Trp) despite 
repeated Sanger sequencing and MLPA analysis of the PAH gene.   
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5.3. Comparison between the results of the early and 
updated patient groups 
The patient group of Paper I was included in the cohort of Paper II. However, in 
1996 the majority of the known 34 PKU patients in Estonia had been diagnosed 
late, after significant clinical manifestations had become obvious and accor-
dingly different extent of damage to psychomotor development had already 
occurred. Thanks to developed diagnostic capabilities, all except one of the 
pathological variations of PAH gene alleles of the patients in Paper I were 
identified by the time of the publication of Paper II, the one that was not 
unveiled was due to lack of material and the patient had disappeared from the 
reach of clinical geneticists. All of these patients had classical type of PKU with 
low tolerance to Phe. 
The analyses performed by the time of the publication of Paper II in 2018 
added ten more pathological variations into the pool of HPA-causing PAH 
alleles in Estonia, while the whole cohort covered 153 independent alleles (from 
unrelated families). Here we could also identify alleles with mild or moderate 
effect on PAH activity (Ala300Ser, Ala403Val), including the ones responding 
to sapropterin hydrochloride administration (Leu48Ser, Arg261Gln), while the 
vast majority of all pathogenic variations remained among the ones with 
deleterious effect on PAH activity. The incidence of the predominant variation 
p.Arg408Trp did not exhibit much change between the two studies: 84% in 
1996 and 80.4% in 2018. Obviously, the launch of newborn screening for PKU 
in 1993 [Ounap et al., 1998] became the cornerstone for constant diagnostic 
supervision for this disorder and enabled also the finding and treatment of the 
few milder versions.  
 
 
5.4. Genotype phenotype correlation of  
Estonian patients with HPA 
Clinically, all our patients known by 1996 exhibited the classical PKU pheno-
type with low phenylalanine tolerance. Variation p.Arg408Trp leaves no resi-
dual enzyme activity [Kayaalp et al., 1997] and the fact that our patient group is 
balanced explains its clinical homogeneity. 
The same is characteristic for the patients presented in the later study (Paper 
II). The vast majority of Estonian PKU patients (87%) exhibit the classical PKU 
phenotype with high Phe levels, which if untreated, is due to minimal or zero 
PAH activity. This is in good correlation with the genotypic data, as the varia-
tions p.Arg408Trp, p.Arg158Gln, p.Pro281Leu, p.Arg252Trp, p.(?)/IVS12+ 
1G>A [Danecka et al., 2015] retain the mutated PAH negligible residual  
enzymatic activity. Only nine patients exhibited mild HPA, harbouring 
p.Arg261Gln, p.Ala403Val, p.Ala300Ser, p.Glu390Gly beside the p.Arg408Trp 
in the second allele, whereas four patients exhibited good response to BH4 
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supplementation and are constantly on Kuvan® treatment now. Genotype/ 
phenotype correlation of Estonian HPA patients is presented in Table 6. 
We have now obtained a larger cohort of patients and thus we are able to 
present more adequate results about the genotypic and phenotypic distribution 
of Estonian PKU patients. Despite the fact that no PAH deficient patients 
exhibiting mild HPA phenotype have been identified in the pre-screening 
subgroup, the relative frequency (80%) of the major p.Arg408Trp variation has 
remained among the highest across diverse populations. The exceptionally high 
prevalence (84%) of this mutation reported two decades ago in Paper I [Lille-
vali et al., 1996] could have been considered as a result of insufficient diag-
nostic capabilities in the past, leaving mild HPA cases out of the reach of 
paediatricians and clinical geneticists. It may have occurred in single un-
determined cases, but the presence of only six PKU patients exhibiting mild 
HPA phenotype in the whole cohort suggests that this kind of possible diag-
nostic shortcoming must not have been prevalent.  
Our cohort included a relatively small number of BH4-sensitive patients. 
Previous research on BH4 responsiveness in other populations has provided 
evidence on the need to study each patient individually, as the response may 
differ significantly due to the particular molecular structure of the mutant PAH 
protein [Danecka et al., 2015]. However, based on the genotypic structure of the 
Estonian population with high prevalence of the p.Arg408Trp mutation, this 
number is not surprising at all. It has been clearly shown that this mutation is 
responsible for almost complete ablation of the PAH enzymatic activity with no 
change if substrate and cofactor are provided in excess [Danecka et al., 2015]. 
Since 2010, every HPA newborn has undergone a loading test with sapropterin 
hydrochloride, while the patients born earlier were not tested, and therefore in 
our data, three older patients with the p.Arg408Trp/p.Leu48Ser genotype have 
been considered as having classical PKU, and the more recent one as BH4 
responsive. This practice has helped to discover six BH4-responsive patients, 
which enables to provide better quality of life to them and their families.  
In conclusion, Estonia exhibits a notably homogenous mutation pool of 
disease-causing PKU alleles with high prevalence of the classical severe form 
of PKU. Contemporary clinical practices and newborn screening have helped in 
diagnosing a few additional mild HPA cases.  
 
 
  
51 
Table 6. Allelic combinations and phenotype distribution of Estonian PKU patients 
[Lillevali et al., 2018]. 
Genotype (variations in the PAH 
gene) 
Number 
of 
patients 
Frequency 
(%) 
Phenotype  
p.[Arg408Trp];[Arg408Trp] 
c.1222 [C>T];[C>T] 
58 62% Classical PKU 
 
p.[Arg408Trp];[Leu48Ser] 
c.[1222C>T];[143T>C] 
4 4.3% 3 Classical PKU / 1 BH4-
responsive PKU 
p.[Arg408Trp];[(?) / IVS12+1G>A] 
c.[1222C>T];[1315+1G>A] 
3 3.2% Classical PKU 
p.[Arg408Trp];[Pro281Leu] 
c.[1222C>T];[842C>T] 
2 2.1% Classical PKU 
p.[Arg408Trp];[Arg261Gln] 
c.[1222C>T];[782G>A] 
4 4.3% 2 Classical PKU / 2 BH4-
responsive PKU  
p.[Arg408Trp];[Glu390Gly] 
c.[1222C>T];[1169A>G] 
1 1.1% BH4-responsive PKU 
p.[Arg158Gln];[(?) / IVS12+1G>A] 
c.[473>A];[1315+1G>A] 
1 1.1% Classical PKU 
p.[Arg408Trp];[Gln355_Tyr356 
insGlyLeuGln / IVS10-11G>A] 
c.[1222C>T];[1066-11G>A] 
1 1.1% Classical PKU 
p.[Arg408Trp];[Arg252Trp] 
c.[1222C>T];[754C>T] 
4 4.3% Classical PKU 
p.[Arg408Trp];[Asp222*] 
c.[1222C>T];[c.663_664delAG] 
2 2.1% Classical PKU 
p.[Arg408Trp];[Ser349Pro] 
c.[1222C>T];[1045T>C] 
1 1.1% Classical PKU 
p.[Arg408Trp];[Ile306Val] 
c.[1222C>T];[916A>G] 
2 2.1% Mild HPA 
p.[Arg408Trp];[Glu280Lys] 
c.[1222C>T];[838G>A] 
2 2.1% Classical PKU 
p.[Leu48Ser];[Glu280Lys] 
c.[143T>C];[838G>A] 
1 1.1% Classical PKU 
p.[Arg408Trp];[Ile65Thr] 
c.[1222C>T];[194T>C] 
1 1.1% Classical PKU 
p.[Arg408Trp];[Ala300Ser] 
c.[1222C>T];[898G>T] 
2 2.1% Mild HPA 
p.[Arg408Trp];[Ala403Val] 
c.[1222C>T];[1208C>T] 
1 1.1% Mild PKU 
p.[Arg408Trp];[NA] 
c.[1222C>T];[NA] 
1 1.1% Classical PKU 
p.[Arg408Trp];[NA] 
c.[1222C>T];[NA] 
1 1.1% Mild PKU 
c.[NA];[NA] (no DNA) 2 2.1% Classical PKU 
Total 94 100%  
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5.5. The comparison of the spectrum of PAH gene 
variations among distinct ethnic groups in Estonia  
We revealed, that among the patients of Estonian origin, the incidence of 
p.Arg408Trp is even higher than in Slavic and mixed groups and in the whole 
population (87.5, 75 and 81.3%), respectively [Lillevali et al., 1996]. The rela-
tive frequency of p.Arg408Trp in the Slavic group is close to other Slavic popu-
lations as described before [Charikova et al., 1993; Eisensmith et al., 1995]. 
Statistical χ2 analysis did not reveal a significant difference in the distribution of 
the p.Arg408Trp allele among ethnically distinct groups of the Estonian popul-
ation – the Estonians and Russians (approximately 30% of the Estonian popu-
lation). 
The ethnic structure of Estonian PKU patients resembles the general ethnical 
structure of the republic. Out of the 94 patients, 63 (67%) were Estonians, 24 
(26%) Slavic (Russian or Ukrainian) and seven of mixed origin, including Esto-
nian, Latvian, Armenian and Azerbaijan [Lillevali et al., 2018]. This structure is 
highly similar to general Estonian population, which comprises mostly of Esto-
nians (68.8%) and people of East Slavic ethnicities (27.8%), according to Statis-
tics Estonia (http://www.stat.ee) (01.01.2016).  
Accordingly, no differentiation between distinct ethnic groups for the inci-
dence and genotypic variability of PKU in Estonia can be drawn.  
 
5.6. The geographical distribution of the variation 
p.Arg408Trp in the PAH gene inside Estonia 
An interesting observation, derived from the genealogical data and the localisa-
tion of the birthplaces of the grandparents carrying the prominent p.Arg408Trp 
variation, is that a significant proportion of these are located in the relatively 
sparsely populated areas of Southern and South-Eastern Estonia. Statistical 
analysis of the birthplaces of the grandparents of PKU patients of Estonian 
ethnicity carrying the p.Arg408Trp variation revealed several counties of 
Estonia providing higher input of this allele into Estonian PAH variation pool. 
Considering the population density, the local ‘hotspot’ of p.Arg408Trp locates 
to three (and one former) counties of South-Eastern Estonia, especially to 
former Petseri County, as well as Võru, Põlva and Valga Counties (3.5, 2.63, 
2.04 and 2.01 carrier origins per 10,000 Estonians, respectively), while the 
number of p.Arg408Trp carrier origins per 10,000 Estonians for the whole 
country was 0.88. Relatively high input came from Estonian bigger islands, 
Saaremaa and Hiiumaa, exhibiting similar disproportionally high ratio of birth-
places of putative p. Arg408Trp carrying grandparents. However, with wider 
confidence limits; a ‘hotspot’ was also found in North-Eastern Ida-Viru County 
(2.1 carrier origins per 10,000), while Northern, Western mainland and Central 
Estonia had relatively few carriers in comparison with their population density 
(Table 7). The birthplaces of 160 grandparents of PKU patients were marked on 
53 
a map with red dots and presented in Figure 6. Each dot shows the origin of 
p.Arg408Trp with 50% probability [Lillevali et al., 2018]. We speculate for a 
possible bottleneck effect or genetic drift, as the period of plagues in the 17th 
century as well as the tremendous population loss due to the Great Northern 
War in the beginning of the 18th century may have led to the observed distri-
bution of this particular allele.  
 
 
 
Table 7. Relative impact of geographically distinct regions of Estonia (counties) to 
historical formation of Estonian pool of PAH alleles carrying the p.Arg408Trp variation 
[Lillevali et al., 2018].  
County 
No of 
grand-
parents 
All 
residents Estonians 
p. Arg408Trp 
carrier count 
per 10,000 
Estonians 
Lower 
Confidence 
Limit 
Upper 
Confidence 
Limit 
Harjumaa 30 524,938 314,490 0.48 0.2702789  0.6677478 
Hiiumaa 4 10,097 9,930 2.01 0  4.5317221 
Ida-Virumaa 14 169,688 33,343 2.10 0.8997391  3.2990433 
Järvamaa 2 36,130 33,803 0.30 0  0.7395793 
Jõgevamaa 4 36,780 33,234 0.60 0.1504483  1.2035867 
Lääne-
Virumaa 8 67,151 57,239 0.70 0.2620591  1.2229424 
Läänemaa 1 27,477 24,124 0.21 0  0.6217874 
Pärnumaa 7 88,466 77,522 0.45 0.0644978  1.0319651 
Petserimaa 11 48,536 15,706 3.50 0.955049  6.3669935 
Põlvamaa 12 31,002 29,371 2.04 0.8511797  3.234483 
Raplamaa 8 36,678 34,235 1.17 0.4381481  2.0446911 
Saaremaa 11 34,723 34,139 1.61 0.2929201  3.0756613 
Tartumaa 14 150,139 127,498 0.55 0.2352978  0.9411912 
Valgamaa 10 30,176 24,934 2.01 0.8021176  3.4089998 
Viljandimaa 7 55,657 52,501 0.67 0.1904726 1.2380717 
Võrumaa 19 37,888 36,069 2.63 1.3862319  3.8814494 
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Figure 6. Geographical distribution of the origins of the p.Arg408Trp variation in the 
phenylalanine hydroxylase (PAH) gene in Estonia. Birthplaces of the grandparents of 
PKU patients with the p.Arg408Trp variation in the PAH gene are shown with red dots. 
Note that each dot presents 50% probability of the grandparent being a carrier of the 
variation [Lillevali et al., 2018]. 
 
5.7. The prevalence of PAH deficiency in Estonia 
The number of live births in Estonia during 1993 to 01.09.2016 was 321,210. 
This number was divided by 48, the number of the second sub-cohort of HPA 
patients, and thus the prevalence of PAH-dependent HPA-s in Estonia was 
estimated as 1 in 6,700. Although some newborns miss from the screening 
programme due to lack of parental consent, the likelihood of missing a PKU 
patient from medical observation during last 24 years is negligible; therefore, 
total national statistics of live births was used. The two probands of Estonian 
origin  born in Belgium and one prenatally terminated diagnosed pregnancy 
were taken into account when determining the prevalence of PAH-deficient 
HPA-s [Lillevali et al., 2018]. 
It has been a subject of discussions that heterozygosity for PAH deficiency 
might possess some selective advantage, as suggested by the prevalence of PKU 
in distinct populations and with a wide diversity in the mutational spectrum 
[Saugstad 2006; Zschocke 2003]. We speculate for a possible bottleneck effect 
or genetic drift, as the period of plagues in the 17th century as well as the tre-
mendous population loss due to the Great Northern War in the beginning of the 
18th century may have led to the observed distribution of this particular allele.  
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5.8. The adherence of dietary therapy among  
Estonian PKU patients (Paper III) 
Among all of Estonian PKU patients, we found the median of medians of Phe 
values during the observed period as 394 µmol/l, reflecting that approximately 
half of the patients were able to sustain the recommended dietary treatment for 
half of the measurement instances. The summary of the average Phe levels for 
the whole cohort is presented in Figure 7. Only four of the 60 patients never 
exceeded the recommended Phe level during the entire evaluation period. Only 
one patient of these four had the benign PKU phenotype, with the other three 
having classical PKU. As this assessment took into account all entries (N = 
4236, 60 individuals) without discrimination of the age of the patient, the regu-
larity of observations, or concomitant health problems, next we therefore split 
the database into more distinct age groups. 
We divided the whole cohort into six age groups to give insight into the 
actual values of blood spot Phe during various periods of growth and life, taking 
into account the proposed values from the Guidelines.   
All values of blood spot Phe analyses presented in relation to the recom-
mended cut-off values in Estonia are shown in a diagram (Figure 8). All data 
are presented in groups by age of the patients. Figure 8 shows the percentage of 
patients in an age group with median Phe values falling below the national 
recommendation levels of the respective age.  
 
 
Figure 7. Average Phe values of all Estonian PKU patients of ages 0 to 18 years 
together during 2010 to 2018 (N = 4236)  [Lillevali et al., 2019]. 
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5.8.1. Age group 0 to 1 years 
The results of the age group of 0-1year (19 patients, Estonian reference value 
240 µmol/L; European reference value 360 µmol/l – results given in brackets) 
were remarkably good for this cohort: for 79% of all measurements and 95% of 
the patients, the median Phe values were within the range of the nationally-re-
commended levels (Figures 8 and 9). There were three (five) patients whose 
Phe value never exceeded the recommended level, while for six (nine) patients 
the elevated levels occurred in less than 10% of cases, likely referring to occa-
sional fluctuations possibly due to infections or random uncontrolled ingestions 
of unchecked products. In three patients, the elevated levels occurred between 
10 and 20%, while four patients exhibited elevated levels in 50, 44 and 35 % of 
measurements, which may indicate that the latter families were not able to con-
sistently follow the advised dietary instructions. The median number of samples 
arriving to the laboratory was 35, which is lower than the recommended weekly 
frequency, but still reflects the desire of the families to adhere to the recom-
mendations. During the first year of life, three of the patients, all with classical 
PKU, never exceeded the recommendation of 240 µmol/L Phe level [Lillevali et 
al., 2019].   
 
Figure 8. All entries (N = 4236) of blood spot Phe values of Estonian PKU/HPA 
patients in LIMS of UL-TUH are shown on a diagram regarding recommended limits as 
percentage along age groups. The diagram presents generalized overview of adherence 
to dietary recommendations in particular age groups and draws out the proportion of 
samples in well-managed patients and cases with lower dietary adherence [Lillevali et 
al., 2019]. 
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5.8.2. Age group 1 to 2 years 
The results of the age group of 1-2year (19 patients) exhibited some change 
compared to 0-1y: for 77% of all measurements and 84% of the patients, the 
median Phe values were in the range of the nationally-recommended levels (Fi-
gures 8 and 9). The median of medians of Phe values remained at 224 µmol/L, 
suggestive of generally acceptable adherence to diet. The group contained the 
same 19 patients as the 0-1y cohort, however in only three patients did the Phe 
value exceed suggested recommendations (360 µmol/L) in no more than 10% of 
measurements, while six patients exhibited elevated levels in more than 25% of 
cases, including two patients whose Phe values did not fit into the recom-
mended level for a single time. Similarly to the first age group, the median 
count of samples per patient was 32, being in good accordance with the fort-
nightly recommendation [Lillevali et al., 2019].  
 
 
5.8.3. Age group 2 to 6 years 
In this group of 20 patients, for 63% of all measurements and 70% of the pa-
tients, the median Phe values were in the range of the nationally-recommended 
levels (Figures 8 and 9). The median of medians of Phe values was 285 µmol/L, 
but on the background of drastically diverging individual scores, the adherence 
to diet seems more questionable. In only four patients did elevations above the 
recommendation (360 µmol/L) occur in less than 10% of cases; three of them 
having classical PKU and one has BH4-sensitive PKU. In three patients, the 
elevated levels occurred between 10 and 25% of samples, and all the remaining 
13 patients exceeded the level more frequently, with four of them exceeding the 
level in 90-100% of entries, reflecting severe difficulties in keeping the diet.  
Additionally, the sampling frequency deviates substantially: while the families 
of some patients send the samples even more frequently than recommended, the 
others either are seemingly attached to the dietary routine and feel confident, or 
have lost interest in constant monitoring [Lillevali et al., 2019].  
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Figure 9. Median blood spot Phe values of Estonian PKU/HPA patients (N = 60) are 
shown in the diagram as percentage fitting under the recommended national values 
according to age groups. Here the medians of gathered blood spot values of each patient 
are assembled into the graph to present the proportion of well-managed individual diet 
among every age group [Lillevali et al., 2019]. 
 
5.8.4. Age group 6 to 12 years 
In the age group of 6–12 year (19 patients), for 46% of all measurements and 
43% of the patients, median Phe values were in the range of the recommended 
levels (Figures 8 and 9). The tendency for elevated Phe increased as shown 
earlier (recommended 360 µmol/L).  For only three cases of 19 patients was an 
elevated Phe level observed in less than 10% of entries, including one patient 
with mild HPA. Simultaneously, 11 of the patients had Phe increase above  
360 µmol/L in more than 50% of analysed samples. This high ratio of elevated 
results may refer to difficulties in maintaining the dietary regimen in rapidly 
changing social context of early school years. Blood spot sampling frequency 
also declined in this age group, as the median number of samples per patient 
was only 14 during six years. Only in single cases did sampling occur monthly 
[Lillevali et al., 2019].  
 
 
5.8.5. Adolescent group of 12 to 18 years 
Referring to the Guidelines, the recommended Phe levels of the adolescent 
group of 12–18y (16 patients) should not exceed 600 µmol/L. For 79% of all 
measurements and 59% of the patients, the median Phe values were in the range 
of the nationally recommended levels (Figure 9).  The distribution of elevated 
values among patients was notably more variable than in the younger groups: 
while in half of the patients, the ratio of elevated Phe samples remained in the 
limits from 0 to 40% of measured samples, another half exceeded the re-
commended level in more than half of the measured cases. Here we also 
observed relatively low activity in sending blood samples, as the median count 
was 14.5 [Lillevali et al., 2019].  
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5.8.6. The adult group of 18+ years 
In the adult group of 18+ years (27 patients), the results varied even more 
widely, and for 68% of all measurements and 57% of the patients, the median 
Phe values were in the range of the nationally-recommended levels (Figure 9). 
For three patients, the Phe value never exceeded the recommended level, two of 
them having late-diagnosed classical phenotype, and one with a mild PKU 
version. In five cases exceeding the value happened only once or twice, and 
each of these were individuals with classical phenotype, late diagnosis and 
p.Arg408Trp/p.Arg408Trp genotype; and one from screening, classical pheno-
type, not taking into account those who presented their samples very rarely. 
Still, in 11 patients the elevated values were present in more than half of the 
measurements. Wide differences occurred in the frequency of sending control 
samples:  from a single sample during the whole period to constant monitoring 
with 100 – 150 samples presented, resulting in a frequency of sampling of up to 
14 to 18 times per year [Lillevali et al., 2019].  
 
 
5.8.7. Assessment of the tendencies of the adherence to diet  
Maintaining acceptable blood Phe levels in PKU patients as suggested in 
national guidelines [Uudelepp et al., 2012; Vockley et al., 2014] or more widely 
agreed among international consortiums [Camp et al., 2014; van Spronsen et al., 
2017b] can be burdensome for families [Walter et al., 2002], even though it is 
clear that adherence to these recommendations is important for avoiding 
undesirable neuropsychiatric symptoms as well as intellectual disability [Didycz 
and Bik-Multanowski 2017; Lindegren et al., 2012].  Our results from the 
Estonian cohort of PKU patients reflect the tendencies of gradually occurring 
deviation from the suggested recommendations over time (Figure 7).  
Previously, similar observations have been presented by Walter et al., 2002, 
wherein about a quarter of all samples from ages 0 – 4 years and 5 – 9 years 
exceeded the recommended level. Similarly, our results show that blood Phe 
concentration was not always maintained below the recommend value [Walter 
et al., 2002].  
The adherence to the recommendations in younger age groups remains 
remarkably higher, while with the increase of age and in adolescence the results 
became increasingly divergent. A report involving data from ten European PKU 
centres has shown similar results, reflecting that these same obstacles are to be 
faced in any country and population [Ahring et al., 2011]. Ahring et al. has 
demonstrated that blood Phe concentrations increase with age, and we observed 
a similar tendency (Figure 7), although we also observed a small decrease in 
average Phe concentrations at the age of 14 to 16 years that is not fully under-
stood. One possible explanation is that dietary control in adolescents may be 
better than reported previously [Ahring et al., 2011]. In comparison with the 
work of Jurecki et al. [Jurecki et al., 2017], our data also show better com-
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pliance with the recommendations in our adolescent patients than the pre-
adolescence age group.  
Our approach was to observe each of the patients during the entire available 
period, up to eight years. The median Phe value for either the whole period or 
selected age gives a better understanding of a particular patient’s general 
adherence to dietary management if fluctuations in Phe over the recommended 
level remain sporadic. However, if the median value is observed to be higher than 
the recommendation, the family may warrant closer attention and observation.  
The variability of dietary adherence was not connected to the severity of the 
genotype, as 20 of the patients with median Phe values under the recommended 
reference have the PAH genotype fully depleting PAH activity (14 of them are 
homozygotes for the p.Arg408Trp variant). A few patients exhibited exceeding-
ly elevated Phe levels: nine patients had a median Phe level of 12 mg/dl or 
higher. Phenotypically, they all exhibit the classical PKU phenotype, which is 
in accordance with their genotype, harbouring the predominant p.Arg408Trp 
variation of the PAH gene in one or both of the alleles, and in compound 
heterozygotes the second allele (p.E221D222FSdelAG, p.Arg252Trp, c.1315+ 
1G>A) has been shown to have a deleterious effect on PAH activity. Six of 
these patients had been diagnosed late, before the launch of national screening 
program, providing an explanation to their inability to adhere to the recommen-
dations, as elevated Phe during their infancy had already caused cognitive 
damage. However, three remaining patients were not diagnosed late and ex-
hibited normal progress in education. Surprisingly, five of the late diagnosed 
patients with low educational results manifest well-controlled Phe levels, pro-
bably referring to well established family support or institutional care. 
PKU patients of the same family exhibit usually very similar Phe level patterns; 
in one pair the divergence was greater and, interestingly, in one pair the late-
diagnosed sibling has excellent dietary adherence, while his sister with a more 
timely diagnosis demonstrated more fluctuations and higher median Phe value.  
We observed that during the first two years of life, the families show good 
dietary adherence and follow the recommendations, with the exception of only a 
few families. However, the number of the cases of elevated Phe values sub-
sequently increases with age, especially during early school age (6 to 12 y). In 
adolescence the picture slightly improves, but the relaxed dietary threshold for 
adults is still frequently crossed by most patients.  
The ability to maintain the diet among the patients with classical PKU 
phenotype shows great variability, though, surprisingly, good results were seen 
among a few late-diagnosed patients, even those with poor cognitive func-
tioning. There were only four patients in our cohort whose Phe values have 
been constantly under the reference value: one with benign HPA, other with the 
classical PKU version, while two of the latter belong to the group of late-
diagnosed patients.  
Our data reflect similar tendencies observed previously in studies from diffe-
rent PKU management centres, that an increase in cases of elevated Phe levels 
is seen in parallel with age.  
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5.9. The molecular lesion in the patient with  
DHPR deficiency (Paper IV)  
The following part of the study comprises the final results of an Estonian patient 
with biochemically diagnosed DHPR deficiency, but whose molecular diagnosis 
remained unsolved during 27 years.  
 
5.9.1. Sanger and exome sequencing 
Despite repeated sequencing of the exonic regions with the flanking areas of the 
QDPR gene in the proband and both parents, no pathogenic variations were 
determined. 
 Singleton ES failed to reveal pathogenic variants in QDPR gene or in other 
genes involved in pterin metabolism. However, ES analysis indicated homozy-
gosity around the QDPR gene locus, as only homozygous variants were 
detected in 10 Mb region chr4:7433652-17817262 (GRCh38). 
 
5.9.2. Genome sequencing 
Following the initial investigations, predominantly after obtaining the results 
from ES, the main hypothesis was that the patient may have a homozygous non-
coding rearrangement which disrupts QDPR expression. To explore this hypo-
thesis, trio genome sequencing (GS) was performed. Although there were no 
rare coding variants, concordant with previous studies, two rare homozygous 
intronic variants in the 3’ region of QDPR were detected (c.*119+4759T>C and 
c.*119+12119G>A, ENST00000513615). Both variants were heterozygous in 
both parents. In the gnomAD database, both variants have an allele frequency 
below 0.1% with no homozygotes [Karczewski et al., 2019]. However, as the 
functional consequence is difficult to predict for intronic SNVs, we searched 
further for other classes of variants. By visual inspecting aligned sequencing 
reads, a possible structural variant (SV) breakpoint at Chr4(GRCh38): 
g.17505522 (Figure 10 C) was detected, which locates to intron 2 of QDPR. 
The other breakpoint was discovered by paired read mapping and split read 
analysis, revealing it localised to intron 8 of the ACOX3 gene (Chr4(GRCh38): 
g.8398067) (Figure 10 C). Thus, a possible 9 megabase (Mb) inversion in 4p 
was suspected (Figure 10 A,B). We also performed post hoc analysis using 
three structural variant callers on GS data: Manta [Chen et al., 2016], DELLY 
[Rausch et al., 2012], and Smoove [Layer et al., 2014]. All three SV callers 
detected the inversion and genotyped it as homozygous in the proband and 
heterozygous in both parents. To validate the inversion we designed oligo-
nucleotide primers to perform PCR amplification, and subsequent Sanger 
validation around the breakpoints (Figure 10 B). As expected, the proband did 
not have any PCR product using F1-R1, and F2-R2 primer pairs, whereas F1-F2 
and R1-R2 primer pairs gave PCR product with predicted sequence over both 
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breakpoints (Figure 10 D). This 9-Mb inversion was not observed in 10,782 
unrelated genomes with SV calls in gnomAD [Collins et al., 2019]; in fact, no 
inversions within 544 kb of QDPR were observed in gnomAD, further sup-
porting the rareness and probable pathogenicity of this inversion. Importantly, 
gnomAD database has 2297 Estonians in its GS dataset, thus we can conclude 
that this inversion is very rare among Estonians as well. Homozygosity map-
ping from GS data was performed using PLINK 1.9 [Chang et al., 2015], and 
the homozygous stretch encompassing the inversion was confirmed for the 
region chr4:7452118-18823503 (GRCh38), and no other homozygous stretches 
larger than 5 Mbs were detected, thus excluding the parental consanguinity. The 
detected inversion was submitted to ClinVar database (accession number 
SCV000898485) and to the locus-specific PNDdb [Lillevali et al., 2020].  
 
 
Figure 10. (A) Chromosome 4 ideogram. The described 9-Mb inversion is marked by 
the red box. (B) Scheme of the inversion in the context of ACOX3 and QDPR genes. F1, 
R1, F2, R2 schematically represent the PCR primer design relative to the reference 
(WT) genome. (C) The aligned sequencing reads around detected breakpoints BP1 and 
BP2 visualised using The Integrative Genomics Viewer (IGV). Soft-clipped nucleotides 
are highlighted and nucleotides shown. (D) Validation studies confirming the variant by 
PCR using primers F1-R1 and F1-F2. C – child, M – mother, F – Father, WT – wild-
type control [Lillevali et al., 2020]. 
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5.9.3. Chromosome analysis 
After finding the large inversion, we investigated whether the inversion could 
be detected with a regular chromosomal microscopy analysis (karyotyping with 
G bands) in both heterozygous parents. Our result showed that the inversion of 
4p16.1-p15.32 is not detectable by GTG-banding techniques, as inversion 
points 4p16.1 and 4p15.32 form symmetrical pattern around the band 4p16.2 
(Figure 11). Accordingly, in spite of the almost 10 Mb size of the inversion, the 
inversion is not detectable by G-banding. 
 
 
Figure 11. Karyotype analysis from peripheral blood lymphocytes of the parents of the 
DHPR deficient proband with 9 Mb inversion does not reveal observable pattern 
abnormality [Lillevali et al., 2020]. 
 
5.9.4. mRNA analysis 
For the identification of variants in QDPR, we performed mRNA studies to 
analyse the integrity of the cDNA by PCR in heterozygous parental samples (no 
RNA samples were stored from the proband). This analysis did not reveal any 
different patterns between the parents of the proband and the control, thus 
indicating the lack of possible mRNA products with abnormal length (Figure 
12). Despite the qualitative essence of the performed reactions, a hint for 
decreased quantity of obtained QDPR cDNA could be retrieved from the 
visually observed lower intensity of the PCR products of the parents compared 
to the ones from the control. 
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Figure 12. PCR analysis of QDPR from the cDNA obtained from peripheral blood 
mRNA of the parents of the proband and control. No products of abnormal length can 
be observed, predicted 809 and 716 bp fragments are present. neg: includes all ingre-
dients and primers without cDNA; marker: SolisBiodyne 100 bp DNA ladder [Lillevali 
et al., 2020]. 
 
 
5.9.5. The importance of genome sequencing in  
solving the molecular diagnosis 
The case illustrates the advantages of GS and the clinical importance of struc-
tural variants (SVs) in disease-associated genes. In this family, GS enabled the 
resolution of a 27-year-long diagnostic odyssey, and now provides the pos-
sibility to adequately counsel and test family members at risk for being carriers 
for this disorder. Since the parents are non-consanguineous, but carry the same 
inversion and haplotype, this variant may not be unique to this family.  
SVs, including inversions, are well recognized as a disease mechanism 
[Collins et al., 2017], but balanced SVs in particular remain difficult to detect 
using common molecular DNA variant detection assays that typically focus 
only on the coding regions of the genome. Heterozygous and hemizygous inver-
sions are known to cause many different disorders. However, karyotyping does 
not allow for the identification of exact breakpoints and thus the discovery of 
disrupted genes.  
To our knowledge, this is the first report on a large, canonical homozygous 
pathogenic inversion detected by GS. In addition to simple inversions, GS can 
be used to resolve more complex SVs, where inversions may be accompanied 
by deletions or duplications [Sanchis-Juan et al., 2018].  
The second breakpoint of our patient’s inversion was mapped into the 
intronic area between exons 8 and 9 of the ACOX3 gene encoding pristanoyl-
CoA oxidase. This enzyme has been shown to be involved in the degradation of 
the branched-chain fatty acids [Ferdinandusse et al., 2018; Vanhooren et al., 
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1997], but its deficiency is probably compensated by other peroxisomal acyl-
CoA oxidases and is unlikely to be causing disease in our patient.  
From a clinical perspective, the current report presents an additional strategy 
for making a molecular diagnosis, if biochemical features are suggestive of a 
disorder and conventional or even the most up- to-date methods fail to identify 
the causative variant. Although high-throughput targeted sequencing has been 
shown to be very effective in solving BH4-deficient HPAs [Trujillano et al., 
2014], our case reiterates the additional benefits associated with GS. This 
inversion maintained all of the exons of QDPR intact, as the breakpoint oc-
curred deep inside of an intron, thus presented completely normal results from 
PCR and Sanger sequencing as well as ES. Obviously, the presence of a break-
point inside a gene eliminates the possibility of synthesizing normal functional 
mRNA and respective protein. Standard cytogenetic methods were not capable 
of revealing this inversion. After mapping the breakpoints in the genome of the 
index patient, further diagnostic testing in the family can be performed by 
simple PCR reactions like those presented in Figure 10D, and/or Sanger se-
quencing, enabling significantly faster analysis and consultation. 
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6. CONCLUSIONS  
1. The studies on the genotype and phenotype of Estonian HPA patients were 
published in 1996 and 2018, providing an overview of the cohort of our 
patients with an interval of two decades. Our cohort consisted of 34 patients 
in 1996 and 94 patients in 2018.  
1.1. Estonian patients with HPA have a relatively homogenous pool of 
phenylalanine hydroxylase variations. Most common of all affected 
alleles is p.Arg408Trp (80.4%), which is specific for Eastern Europe 
and exhibits the highest proportion known in all previously described 
populations. This predomination was even higher in the study from 
1996 (84%). 
1.2. The spectrum of pathogenic variations has widened to seventeen 
variations in the PAH gene compared to the study performed in 1996, 
when six variations were determined.  
1.3. A vast majority of Estonian patients exhibit classical PKU (87%) with 
low tolerance to Phe in nutrition and high pre-treatment Phe levels. 
1.4. In the refreshed cohort of 94 patients, four patients receiving BH4 
treatment were found, two with mild PKU with moderate elevation of 
Phe, and four patients with mild manifestation of HPA, who do not 
receive specific treatment for lowering their Phe values. 
 
2. The distribution of PKU among Estonian patients could not be distinguished 
ethnically; the proportions of ethnic Estonians and people of Slavic ethnic 
background (Russians, Ukrainians) were similar to the ethnic proportions in 
the population of the country.  
 
3. The local domicile of the ancestors of the PKU patients of Estonian ethnicity 
harbouring the most widely distributed pathological version of PAH, the 
p.Arg408Trp variant, revealed that the hotspot of the origin of p.Arg408Trp 
in Estonia is located mostly to Southern and South-Eastern Estonia, to Põlva, 
Võru and Valga counties, and especially to former Petseri county. 
 
4. In the adherence to dietary therapy, Estonian PKU patients follow similar 
behavioural pattern as the patients described elsewhere. 
4.1. During the early childhood, rather well-maintained Phe levels during 
the constant follow-up were observed (with a few deviations in single 
families). 
4.2. The situation worsens with the start of elementary school, when the 
median of analyses elevates the nationally recommended levels for 57% 
of the patients. 
4.3. The adherence to dietary therapy improves during adolescence (43%) 
and remains similar in adults. 
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4.4. As an interesting observation, some late-diagnosed adult patients with 
variable levels of disability, exhibit exceptionally good adherence to the 
dietary therapy. 
4.5. The laboratory information management system of Tartu University 
Hospital enables personal tracking of each patient as well as obtaining 
generalised view of different age groups. 
 
5. The patient with biochemically diagnosed DHPR deficiency was subjected 
to multiple molecular and cytological diagnostic methods, but the existing 
molecular lesion was discovered by genome sequencing. 
5.1. Genome sequencing identified a homozygous 9-Mb inversion in chromo-
some 4, harbouring a structural variant breakpoint at Chr4(GRCh38): 
g.17505522 in intron 2 of QDPR gene, and another breakpoint in intron 
8 of the ACOX3 gene at Chr4(GRCh38):g.8398067. 
5.2. The observed structural variant has never been described before and is 
obviously causative for the ablation of DHPR activity. 
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SUMMARY IN ESTONIAN  
Hüperfenüülalanineemiad ja seotud  
neurofüsioloogilised häired  
Fenüülalaniin (Phe) on üks 20-st tavatoidu valkudes esindatud aminohappest, 
mis normaalse ainevahetuse puhul hüdrolüüsitakse türosiiniks. Kui selle prot-
sessi eest vastutav ensüüm fenüülalaniini hüdroksülaas (PAH) ei toimi korrekt-
selt, tekib organismis hüperfenüülalanineemia (HPA) – seisund, mille püsimisel 
võib kujuneda vaimne ja motoorne mahajäämus. Peamine HPA sümptomaati-
kaga ainevahetushaigus on fenüülketonuuria (PKU, OMIM #261600), auto-
somaalse retsessiivse päritavusega häire, mis kuulub tuntuimate ja levinuimate 
ainevahetushaiguste sekka, sagedusega ca 1:10 000 vastsündinu kohta valge 
rassi seas [Williams et al., 2008]. PKU on ravitav, kui eemaldada igapäevasest 
toidust võimalikult suurel määral tavaline valk ja asendada see aminohapete 
seguga, millest puudub Phe [Blau and Scriver 2004; Blau et al., 2010; Blau N 
2014; Scriver 1995]. 
PKU olemusest hakati aru saama 1930ndatel aastatel, mil Norra arst Asbjørn 
Følling avastas grupi vaimse mahajäämusega patsientide uriinist Phe alterna-
tiivse metaboliidi fenüülpüruvaadi, mille kaudu haigust hakati kutsuma PKU-ks 
[Centerwall and Centerwall 2000; Folling 1994]. 1950. aastatel avastati fenüül-
alaniinivaese dieedi oluline kasulikkus PKU patsientidele ja selle tulemuslikkus 
seostati ravi varajase alustamisega. [Bickel et al., 1953].  
USA mikrobioloog Dr Robert Guthrie töötas välja meetodi Phe taseme 
tuvastamiseks filterpaberile kogutud vereplekist ning tema algatusel alustati Phe 
taseme rutiinset määramist vastsündinutel. Test seisnes kindla bakteritüve 
võimes kasvada ainult kõrgenenud Phe taseme juuresolekul. [Guthrie and Susi 
1963]. Dr Guthrie järgi tuntakse vastsündinute sõeluuringuks kasutatavaid 
filterpabereid Guthrie kaartidena. Arenenud lääneriikides loodi PKU varajaseks 
avastamiseks riiklikud vastsündinute sõeluuringu-programmid, millele lisandus 
järk-järgult ka programme teiste ravitavate ainevahetushaiguste varajaseks 
tuvastamiseks ja rutiinseks testimiseks. [Therrell et al., 2015]. Tänapäevaks 
katab vastsündinute sõeluuring hulka ravitavaid ainevahetushaigusi ja riiklikud 
programmid on üles ehitatud, võttes arvesse iga populatsiooni geneetilist 
struktuuri ja tehnilist võimekust [Bodamer et al., 2007; Burgard et al., 2012; 
Landau et al., 2014; Lindner et al., 2010].  
Eestis diagnoositi kuni 1990. aastate alguseni PKU-d ainult Føllingi testi 
abil, mis määrab uriinist fenüülpüruvaati [Folling 1994] ja eeldati, et tegu on 
väga haruldase haigusega nagu Soome populatsioonis, kus oli PKU sageduseks 
hinnatud umbes 1 patsient 200 000 sünni kohta [Guldberg et al., 1995]. Alates 
1990. aastate algusest asuti Eestis suurt tähelepanu pöörama ravitavate aine-
vahetushaiguste leidmisele ning 1993. aastal käivitati riiklik vastsündinute 
sõeluuring PKU suhtes [Ounap et al., 1998]. Tänaseks toimub SA TÜ Kliini-
kumi ühendlabori kliinilise geneetika keskuses riikliku sõeluuringu programmi 
raames otsing 20 ravitava ainevahetushaiguse suhtes, neist 19, sealhulgas PKU 
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leidmiseks kasutatakse alates 2014. aastast tandem mass-spektromeetrilist 
(MS/MS) analüüsi [Reinson et al., 2018].  
Käesolev töö sai alguse 1990 aastate esimesel poolel, kui Eesti PKU patsien-
tide kohta said tehtud koos prof. K. Õunapiga esimesed epidemioloogilised ja 
molekulaarsed uuringud, mis kajastuvad käesolevas doktoritöös hõlmatud 
publikatsioonis I [Lillevali et al., 1996]. Praeguseks ajaks on tekkinud vajadus 
ajakohastada meie andmeid ja teha need kättesaadavaks meedikutele ja teadlas-
konnale, uurida dieetravi tõhusust koos meie patsientide ja nende perekondade 
võimekusega pidada kinni ettenähtud raviskeemidest. Kuna madala Phe hoid-
mine dieedis on peredele omaette lisakoormus, vajasime ülevaadet meie 
patsientide (ja perede) võimekuse kohta pidada kinni ravijuhistes ettenähtud 
soovitustest lubatava Phe taseme kohta patsiendi veres. Tänu alates 2010. 
aastast TÜ Kliinikumis toimivale e-labori süsteemile saime koostada andme-
baasi kõikidest kirjetest, mis on seotud Eesti PKU patsientide vereanalüüsidega 
Phe taseme suhtes, hinnata iga patsiendi ravi dünaamikat individuaalselt ja 
samuti üldistada dünaamikat ajas ja vanusegruppide vahel. 
PAH ensüümi toimimiseks on vaja piisava hulga koensüümi tetrahüdro-
biopteriini (BH4) olemasolu. Seetõttu võib HPA seisundi põhjustada ka takistus 
BH4 sünteesi või regeneratsiooni biokeemilistes radades. Kõnealused juhtumid 
on PKUst oluliselt haruldasemad, kuid ka keerulisemad ravida ja sageli raskema 
kulu ja halvema prognoosiga. Eestis sündis 1991. aastal laps, kellel diagnoositi 
koostöös Leedu, Šveitsi ja Saksamaa arstidega biokeemiliselt ensüümi di-
hüdropteridiini reduktaasi (DHPR) puudulikkus. DHPR ensüüm vastutab BH4 
regenereerimise eest, sest see kofaktor oksüdeeritakse igakordse Phe (ja ka 
türosiini ning trüptofaani) hüdroksüülimise käigus. Seni oli selle DHPR puudu-
likkusega patsiendi haiguse täpne molekulaargeneetiline põhjus teadmata.  
 
Käesoleva uuringu eesmärgid 
1. Määrata Eesti hüperfenüülalanineemiaga patsientide genotüübid ja korre-
leerida need fenotüüpidega (artiklid I ja II);  
2. Võrrelda PAH geeni variantide spektrit Eesti etniliste rühmade seas (artiklid 
I ja II); 
3. Hinnata kõige levinuma PAH geeni patoloogilise variandi p.Arg408Trp 
geograafilist levikut Eestis (artiklid I ja II); 
4. Uurida, kui korrektselt Eesti PKU patsiendid suudavad järgida dieetravi 
soovitusi  (artikkel III); 
5. Tuvastada DHPR puudulikkusega patsiendi haigust põhjustav molekulaarne 
muutus (artikkel IV). 
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Patsientide ja meetodite lühikirjeldus 
Eesti PKU-ga patsientide uurimiseks loodi andmekogu, millesse hõlmati 95 
teadaolevat HPA juhtumit sünniaastatega 1974 kuni 2016. Kohort jagunes 
kaheks: enne ja pärast Eestis vastsündinute PKU suhtes sõeluurimise sisse-
viimist, s.o. 1993. aastat sündinud HPA-ga patsiendid.  
PAH patogeensete variantide tuvastamiseks sekveneeriti PAH geeni eksonid 
külgnevate piirkondadega Sangeri meetodil. Levinuima variandi p.Arg408Trp 
tuvastamiseks kasutati ka PAH geeni 12. eksoni PCR amplifitseerimist koos 
järgneva StyI restriktsioonanalüüsiga. Lisaks oli kasutusel PAH geeni MLPA 
analüüs. 
Eesti PKU patsientide genealoogilise uuringu käigus koguti andmed pato-
geenset PAH varianti p.Arg408Trp kandvate eesti rahvusest patsientide vana-
vanemate sünnikohtadest. Sünnikohad kanti Eesti kaardile ja potentsiaalselt 
haigusseoselist varianti kandvate vanavanemate hulka hinnati statistiliste 
meetoditega võrrelduna maakondade rahvastikutihedusega.  
TÜ Kliinikumi Ühendlaboris on kasutusel alates 2010. aastast ühtne andme-
haldustarkvara (e-labor), mille põhjal moodustasime andmebaasi Eesti PKU 
patsientidelt saadud analüüsidest ajavahemikul 2010 kuni 2018 kevadeni. 
Saadud andmekogumist on võimalik hinnata üksiku patsiendi ravi järgimise 
dünaamikat Guthrie kaartidel esitatud kuivatatud vereplekkidest ja teha üldis-
tavaid kokkuvõtteid vanusegruppide kaupa. Phe tasemed vereplekis määrati 
kahe erineva meetodiga, algselt McCamani ja Robinsi kvantitatiivsel fluori-
meetrilisel meetodil, alates 2015. aastast aga tandem-MS/MS abil.  
Eestis 1991. aastal sündinud DHPR puudulikkusega HPA patsient sai diag-
noosi biokeemiliste meetodite abil Šveitsis, Zürichis, ja seda ensüümi kodeeriva 
QDPR geeni eksoonsed alad sekveneeriti korduvalt Sangeri meetodiga, tehti 
karüotüpiseerimine, mRNA analüüs vanematelt, eksoomi sekveneerimine. Lõp-
liku vastuse saamiseks tehti täisgenoomi sekveneerimine (GS) ning andme-
analüüs MIT ja Harvardi Ülikooli Broad Instituudi Genoomika platvormil. 
 
Peamised tulemused ja järeldused 
1. Eesti HPA-ga patsientide kohta avaldasime artiklid aastatel 1996 ja 2018, 
millega anname ülevaate meie patsientide kogumist kahe aastakümne pik-
kuse intervalliga. Meie kohordi suurus aastal 1996 oli 34 patsienti ja 2018. 
aastal 94 patsienti.  
1.1.  Eesti HPA-ga patsientidel on suhteliselt homogeenne kogum PAH 
patogeenseid variante. Kõige levinum variant on p.Arg408Trp (80.4%), 
mis on omane Ida-Euroopale ja hõlmab meil suurima osakaalu võrrel-
des teiste seni kirjeldatud populatsioonidega. See ülekaalukus oli isegi 
kõrgem 1996. aastal avaldatud töö andmetel (84%). 
1.2. PAH geeni patogeensete variantide spekter Eestis laienes 17-ni võrrel-
des 1996. aasta uuringuga, mil tuvastati kokku 6 varianti.  
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1.3.  Valdav enamik Eesti PKU patsiente on klassikalise PKU fenotüübiga 
(87%), mida iseloomustab madal tolerants Phe suhtes toidus ja kõrged 
ravieelsed Phe tasemed.   
1.4.  Uuendatud, 94 patsiendist koosnevas kohordis on ainult neli patsienti, 
kes saavad BH4 ravi, kahel on PKU pehme vorm mõõduka Phe taseme 
tõusuga ja neli patsienti, kelle HPA fenotüüp on niivõrd madala Phe 
tõusuga, et nad ei vaja ravi Phe taseme alandamiseks. 
 
2. PKU levimus Eesti etniliste rühmade seas pole eristatav; eestlaste ja slaavi 
(vene, ukraina) taustaga patsientide osakaal on proportsioonis üldiste etni-
liste osakaaludega riigis.  
 
3. Eestlastest PKU patsientide PAH kõige sagedama patoloogilise variandi 
p.Arg408Trp esivanemate päritolu uurimine paigutas kõnealuse variandi 
lähtepiirkonna Kagu- ja Lõuna-Eestisse, eelkõige Põlva, Võru ja Valga maa-
kondadesse ning eriti varasemasse Petseri maakonda.  
 
4. Eesti PKU patsientide dieetravi järgimine sarnaneb teistes riikides kirjelda-
tud olukorraga.  
4.1. Varajases lapseeas on tüüpiline Phe tasemete edukas hoidmine ja pat-
sientide seisundi püsiv järgimine (väheste eranditega üksikute pere-
kondade puhul).   
4.2. Olukord halveneb algkoolieas, mil analüüside väärtuste mediaan ületab 
riiklikutes soovitustes kehtestatu 57% patsientide puhul. 
4.3. Dieetravi järgimine paraneb teismeliseeas (43%) ja jääb sarnaseks 
täiskasvanutel.  
4.4. Osa hilisdiagnoosiga, eri tasemel puudeastmega patsientide dieet on 
eriti korraliku kontrolli all.  
4.5. SA TÜ Kliinikumi laboriinfosüsteem (e-labor) võimaldab nii iga pat-
siendi analüüside tulemuste individuaalset jälgimist kui ka üldistatud 
ülevaate saamist eri vanuserühmadest.  
 
5. Biokeemiliselt diagnoositud DHPR puudulikkusega patsienti uuriti mitmete 
molekulaarsete ja tsütoloogiliste meetoditega, kuid haigust põhjustav mole-
kulaarne hälve leiti kogu genoomi sekveneerimisel.  
5.1. Genoomi sekveneerimine tuvastas homosügootse 9-Mb inversiooni 4. 
kromosoomis, mis tõi kaasa struktuurse variandi murdekohtadega: 
Chr4(GRCh38):g.17505522 QDPR geeni 2. intronis ja ACOX3 geeni 8. 
intronis: Chr4(GRCh38):g.8398067. 
5.2. Leitud struktuurne variant on varasemalt kirjeldamata ja on selge põhjus 
DHPR aktiivsuse kadumiseks.  
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